US Pat. No. 10,653,832

PASSIVE START DRIP CHAMBER

CareFusion 303, Inc., Sa...

1. A passive start drip chamber device comprising:a body having a top portion, a bottom portion, and a chamber that extends from the top portion toward the bottom portion, wherein the bottom portion comprises a first input flow port and an output flow port;
a cap comprising a second input flow port, wherein the cap is coupled with the top portion of the body to enclose the chamber, and a flow path into the chamber extends from the first input flow port to the cap; and
a float positioned within the chamber, between the first input flow port and the cap, the float configured to move between an occluding configuration, wherein the flow path is occluded, and an open configuration, wherein the flow path is not occluded, based on a level of fluid within the chamber.

US Pat. No. 10,653,831

MEDICAMENT DELIVERY DEVICE

Consort Medical, PLC, He...

1. A medicament delivery device comprising:a first container having a delivery outlet at a front end thereof and a first stopper axially moveable in the first container, the first stopper defining and separating a first chamber and a second chamber in the first container, where the first chamber is axially forwards of the first stopper and the second chamber is axially rearwards of the first stopper and configured to receive a propellant; and
a second container having a second stopper axially moveable in the second container, the second stopper defining and separating a third chamber and a fourth chamber in the second container, where the third chamber is axially forwards of the second stopper and the fourth chamber is axially rearwards of the second stopper and configured to receive a propellant, and where the third chamber has a vent outlet in fluid communication with a venting chamber;
wherein the first stopper is directly connected to the second stopper by a tensile member such that axially forwardly movement of the first stopper causes axially forwardly movement of the second stopper due to tensioning of the tensile member; and
wherein the first stopper is drivable in an axially forwardly direction, the first chamber is configured to contain medicament for delivery through the delivery outlet as the first stopper moves axially forwards, the third chamber contains a viscous fluid that enters the venting chamber via the vent outlet as the second stopper moves axially forwards, and the fourth chamber has a pressure that is substantially equal to or greater than the pressure of the venting chamber;
such that as the first stopper is driven axially forwardly, the tensile member is tensioned to pull the second stopper axially forwardly and the venting of viscous fluid into the venting chamber via the vent outlet retards the axially forward movement of the second stopper and the first stopper.

US Pat. No. 10,653,830

INJECTION MECHANISM UTILIZING A VIAL

Becton, Dickinson and Com...

1. A delivery system for dispensing a medicament comprising:a first chamber for storing a supply of the medicament;
a second chamber in fluid communication with the first chamber;
an outlet port for dispensing the medicament, the outlet port being in fluid communication with one of said first and second chambers; and
an orientation indicator for identifying to a user when the delivery system is positioned in a substantially vertical orientation, wherein the orientation indicator comprises a viewing window that becomes available for the user to view the second chamber upon attaining the substantially vertical orientation.

US Pat. No. 10,653,829

AUTOMATIC INJECTOR HAVING DOOR BLOCK UNTIL PROPER CARTRIDGE INSERTION

1. An automatic injector device for delivering a pharmaceutical substance from a cartridge having a protruding edge, said cartridge positioned in a housing of said device, said housing comprising:a cartridge bay having an opening sized to allow passage of said cartridge into said cartridge bay;
a door to said cartridge bay opening, said door having an unlatched position and a latched position, said door being configured to move between the unlatched position and the latched position along a trajectory;
an interference element having a deflected orientation comprising an unstressed configuration of said interference element and an inflected orientation comprising a stressed configuration of said interference element, wherein said interference element is configured to mechanically interfere with movement of said door along said trajectory in said deflected orientation, and wherein said interference element is configured to not mechanically interfere with movement of said door along said trajectory in said inflected orientation; and
a contact interface that is elastic and positioned along said cartridge bay such that when said protruding edge engages said contact interface, said contact interface shifts said interference element into said inflected orientation.

US Pat. No. 10,653,828

SEALED INFUSION DEVICE WITH ELECTRICAL CONNECTOR PORT

Tandem Diabetes Care, Inc...

1. A device for remotely controlling an ambulatory infusion pump, comprising:a housing having a front surface and a back surface that are spaced apart and enclosed by side surfaces to define an internal cavity;
a display disposed on the housing;
a processor disposed within the internal cavity;
an electrical connector port fitted to the housing and extending into the internal cavity, the electrical connector port operably connected to a power isolation integrated circuit chip and a data isolation integrated circuit chip disposed within the housing, the electrical connector port adapted to receive electrical power and data via a direct electrical connection, and direct the electrical power to the power isolation integrated circuit chipo and the data to the data isolation integrated circuit chip; and
wherein the housing and electrical connector port provide a seal preventing passage of moisture into the internal cavity.

US Pat. No. 10,653,827

BLOOD PURIFICATION APPARATUS

Nikkiso Company Limited, ...

1. A blood purification apparatus comprising:a blood circuit including an arterial blood circuit and a venous blood circuit and through which blood of a patient is allowed to extracorporeally circulate;
a blood purifier connected to the blood circuit that is capable of purifying the blood extracorporeally while circulating through the blood circuit;
a dialysate introduction line supplied with a predetermined liquid from a liquid-feeding device and through which a dialysate is introduced into the blood purifier, the liquid-feeding device being capable of feeding the liquid at a constant pressure;
a dialysate drain line through which waste water is discharged from the blood purifier;
a substitution line one end of which is connected to a collecting port provided at a predetermined position of the dialysate introduction line and an other end of which is connected to the arterial blood circuit or the venous blood circuit;
a displacement-type pump provided on the dialysate introduction line or the substitution line:
a closing device provided to the substitution line and that is capable of arbitrarily closing a flow route provided by the substitution line, the closing device being configured to form, in a state where the flow route is closed, a pressure-increasing portion that includes the collecting port; and
a pressure-measuring device capable of measuring a pressure in the pressure-increasing portion,
the blood purification apparatus performing a testing process in which connection of the substitution line to the collecting port is checked by increasing a liquid pressure in the pressure-increasing portion and measuring the pressure with the pressure-measuring device,
wherein the testing process is performed by increasing the liquid pressure in the pressure-increasing portion by utilizing a liquid-feeding pressure applied from the liquid-feeding device, and the liquid-feeding device generates the liquid-feeding pressure by activation of a non-displacement-type or a level difference of the dialysate in the liquid-feeding device relative to the dialysate in the pressure-increasing portion and not by the displacement-type pump.

US Pat. No. 10,653,826

BLOOD TREATMENT AIR PURGING SYSTEMS

Baxter International Inc....

1. A dialysis system comprising:a dialysis fluid circuit;
a blood circuit including
an arterial line,
a venous line, and
an enclosure in fluid communication with the venous line, the enclosure configured to release air through a hydrophobic vent for priming the blood circuit;
a blood pump configured to pump fluid through at least the arterial line;
a first valve operable with the arterial line and a second valve operable with the venous line; and
a pumping and valving algorithm operated (i) to prime the blood circuit to remove air from the blood circuit through the hydrophobic vent, and (ii) to control the first and second valves and the blood pump to replace priming fluid with blood from a patient after priming the blood circuit.

US Pat. No. 10,653,824

TWO-DIMENSIONAL MATERIALS AND USES THEREOF

Lockheed Martin Corporati...

1. A process for forming a blood filtration device, comprising:exposing a multilayered material to ions provided by an ion source, the multilayered material comprising a first layer comprising a two-dimensional first material and a second layer of a second material in contact with the first layer, wherein the ions have an ion energy ranging from 1.0 keV to 10 keV, and a flux from 0.1 nA/mm2 to 100 nA/mm2; and
producing a perforated two-dimensional material by producing a plurality of through-holes in the two-dimensional first material by interacting the ions with the two-dimensional first material and with the second material;
forming at least two of a composite membrane comprising a porous substrate having a plurality of pores and a sheet of the perforated two-dimensional material disposed on a surface of the porous substrate and defining a top surface of the composite membrane, wherein the sheet of the perforated two-dimensional material covers at least a portion of the plurality of pores of the porous substrate and wherein at least one pore of the substrate is not covered by the sheet of the perforated two-dimensional material;
introducing one or more occluding moieties at least partially into the at least one uncovered pore to occlude the at least one uncovered pore;
incorporating at least two of the composite membranes to form the blood filtration device;
forming a cross-linked graphene platelet polymer membrane by reacting an epoxide-functionalized graphene platelet with a (meth)acrylate- or (meth)acrylamide-functionalized cross-linker; and
incorporating the cross-linked graphene platelet polymer membrane, having a plurality of cross-linked graphene platelets, into the blood filtration device,
wherein the plurality of cross-linked graphene platelets have a graphene portion and a cross-linking portion, the cross-linking portion containing a 4- to 10-atom link.

US Pat. No. 10,653,823

WOUND DRESSING WITH MICROPUMP

3M Innovative Properties ...

1. A wound dressing apparatus, which comprises:a wound dressing comprising a backing having an interior surface configured to face a wound and an exterior surface opposite the interior surface, the interior surface of the backing comprising an adhesive area that forms a sealed environment between the interior surface and the wound, and a non-adhesive area comprising a stand-off element, the stand-off element comprising structures defining a plurality of fluid channels; and
a micropump system including a rotorless, self-priming micropump mounted to the exterior surface of the backing such that the micropump is integral with the wound dressing, the micropump comprising an electroactive actuator member, a first chamber for applying subatmospheric pressure to the sealed environment around the wound, and a second chamber for output pressure above atmospheric pressure;
wherein fluid enters an inlet side of the micropump to the first chamber through a normally closed one-way inlet valve, wherein the inlet valve is located in the non-adhesive area or proximate a perimeter of the non-adhesive area, enters the second chamber through a normally closed one-way outlet valve, and exits the second chamber of the micropump to a fluid accumulation device when the sealed environment is under positive pressure relative to the atmosphere, and wherein the channels in the stand-off element maintain removal of the fluid through the inlet valve when the sealed environment is under negative pressure relative to the atmosphere.

US Pat. No. 10,653,821

HAEMOSTATIC DEVICE

SELENTUS SCIENCE LIMITED,...

1. A bioresorbable haemostatic foam sponge for adhering to a wound, the sponge comprising a tissue-contacting surface configured to contact the wound, which surface is divided into a plurality of closely-spaced tissue contacting elements such that there are at least 10 tissue contacting elements per 100 mm2 of tissue-contacting surface,wherein the sponge is manufactured from collagen, starch, gelatin or hyaluronic acid, and
wherein the tissue-contacting elements are columnar, the cross-sectional area of each tissue-contacting element is consistent throughout the depth of the tissue-contacting element, and the cross-sectional area of each face of each tissue contacting element is 50 mm2 or less.

US Pat. No. 10,653,820

COATED STENTS

Micell Technologies, Inc....

1. A coated stent comprisinga. a stent having a plurality of struts;
b. a coating having an active agent and a bioabsorbable polymer, wherein the active agent is a macrolide immunosuppressive drug in crystalline form, wherein the active agent remains in crystalline form after being included in the coating;
wherein said coating is substantially conformal to abluminal, luminal, and sidewall surfaces of the struts of the stent to form a plurality of coated struts and a ratio of an abluminal coating thickness to a luminal coating thickness is at most 90:10.

US Pat. No. 10,653,819

DEVICE FOR REPAIR SURGERY OF CYLINDRICAL ORGANS, PARTICULARLY RUPTURED TENDONS, COMPRISING A THERAPEUTIC AGENT FOR STIMULATING REGROWTH, AND METHOD OF PRODUCING SUCH DEVICE

UNIVERSITAET ZUERICH, Zu...

1. A device for repair surgery of cylindrical organs comprising a tubular sheath (T) made of a mesh of elastic fibers formed by electrospinning at least one biocompatible and biodegradable polymer,said tubular sheath having a Young elasticity modulus of about 0.1 to about 4 MPa and a strain at break of about 50 to about 1,000%, said tubular sheath having a first wall surface and a second wall surface substantially parallel thereto, said first wall surface being smooth (WS) and said second wall surface being rough (WR),
wherein
said elastic fibers comprise
first fibers consisting of a first one of said polymers in neat form, and second fibers consisting of a second one of said polymers with an admixture of a therapeutic agent adapted to stimulate regrowth processes of a predetermined cylindrical organ, said tubular sheath comprising a first tubular region adjacent to said first wall and a second tubular region adjacent to said second wall, said first tubular region being formed of said first fibers and said second tubular region being formed of said second fibers.

US Pat. No. 10,653,818

MAGNETIC NANOPARTICLE EMBEDDED NANOFIBROUS MEMBRANE

UNIVERSITY OF FLORIDA RES...

1. A nanofibrous membrane, comprising:one or more electrospun nanofibers forming a layer of nanofibers affixed to a support structure, the layer of nanofibers extending across an opening of the support structure in a substantially planar orientation and affixed to the support structure along an edge of the opening by a non-toxic glue; and
a plurality of magnetic nanoparticles embedded in the one or more electrospun nanofibers of the layer of nanofibers,
where the layer of nanofibers deflects out-of-plane within the opening of the support structure in response to exposure to a magnetic field passing through the opening of the support structure, where the support structure is a machined printed circuit board (PCB) O-ring with the opening.

US Pat. No. 10,653,817

METHOD FOR PRODUCING AN IMPLANTABLE LIGAMENT AND TENDON REPAIR DEVICE

EMBODY INC., Norfolk, VA...

1. A method for producing an implantable ligament and tendon repair device comprising the steps of:dissolving Type I collagen and a bio-acceptable polymer selected from the group consisting of PDLA, PDLLA, PLGA, and mixtures thereof, in a DMSO solvent system comprising about 40 to 100% by volume of DMSO and about 0 to 60% by volume of a solvent selected from the group consisting of ethanol, tetrahydrofuran and acetic acid to form a biopolymer solution;
generating biopolymer fibers from the biopolymer solution;
collecting the biopolymer fibers to form a biopolymer sheet; and
annealing the biopolymer sheet; and
wherein the biopolymer fibers comprise about 10 to 35% by weight of Type I collagen and about 65 to 90% by weight of the bio-acceptable polymer; and
wherein the biopolymer fibers in the biopolymer sheet are not chemically cross-linked.

US Pat. No. 10,653,811

ARTICLES WITH ODOR-CONTROLLING COMPOSITION

Rem Brands, Inc., Walton...

1. An odor-controlling article, comprising:an absorbent substrate having thereon a halo active aromatic sulfonamide compound of Formula (I):

wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl;
R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and
R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected;
X is halogen;
M is an alkali or alkaline earth metal; and
n is the number of water molecules per molecule of the sulfonamide compound;
wherein the halo active aromatic sulfonamide compound is present in the amount of about 0.0002 to about 6 milligrams per milliliter (mg/mL) of absorbent capacity of the absorbent substrate.

US Pat. No. 10,653,809

SCENT DISPENSING DEVICE

ONOTES, INC., Boston, MA...

1. A scent dispensing device comprising:a housing that has a cavity that forms an interior of the housing, the housing which separates the interior from an external environment which is external to the housing, the interior sized and dimensioned to receive one or more scent cartridges, the housing having a number of apertures which provide respective ones of a number of flow paths between the interior of the housing and the external environment, the housing having at least one portion that is resiliently deformedly physically securable in an internal contour of at least a portion of an object to which the scent dispensing device is physically securable; and
a number of selectively permeable membranes positioned in the flow paths, the selectively permeable membranes which selectively block moisture from reaching the interior of the housing from the external environment, and which permit passage of gas between the interior of the housing and the external environment including passage of at least one scent from the interior of the housing to the external environment.

US Pat. No. 10,653,808

DISINFECTION APPARATUS HAVING SUBMERSIBLE UV LIGHT DEVICES

Bolb Inc., Livermore, CA...

1. An apparatus for disinfecting fluid, comprising:a pipe having first and second linear segments and an elbow that is removably secured to the first and second linear segments;
one or more disinfection devices installed on the elbow to be submersible in fluid, each of the one or more disinfection devices being configured to generate light for disinfecting fluid in a linear segment of the pipe;
a laminar flow enforcer installed inside the first segment of the pipe and configured to generate a laminar flow in the first segment of the pipe; and
an orifice installed inside the first segment of the pipe and having an opening so that an entire flow flowing through the first segment of the pipe exits the opening as one laminar flow pillar,
wherein a diameter of the laminar flow pillar is smaller than an inner diameter of the pipe thereby forming an air gap between the laminar flow pillar and the first segment of the pipe to thereby separate the laminar flow pillar from an inner surface of the first segment of the pipe,
wherein the one or more disinfection devices are located at a downstream end of the laminar flow pillar and transmits the light to a substantially upstream direction of the laminar flow pillar, and
wherein a portion of the light for disinfecting fluid is internally reflected at an interface between the laminar flow pillar and the air gap within the first segment of the pipe, sufficient to disinfect the fluid in the laminar flow pillar.

US Pat. No. 10,653,807

SYSTEM, METHOD AND PROCESS FOR DISINFECTION OF INTERNAL SURFACES IN ASEPTIC TANKS AND PIPELINES BY FLOODING WITH SANITIZING FOG

1. A method for disinfection of internal surfaces of at least one of an aseptic tank and a pipeline configured to store and transport liquids, the method comprising:flooding the at least one of the aseptic tank and the pipeline with an inert gas and a sanitizing fog, the flooding causing oxygen present in the tank to rise to the upper portion of the tank;
detecting the concentration of oxygen in the tank;
removing the oxygen from the at least one of the aseptic tank and the pipeline through a duct and into the atmosphere; and
closing the duct when the detected concentration of oxygen in the tank is less than a predetermined amount.

US Pat. No. 10,653,806

HOMOMULTIVALENT AND HETEROMULTIVALENT INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF

The Johns Hopkins Univers...

1. A compound of formula I:
wherein Z is H, CO2H, NH2, SH and OH;
wherein m is 2 to 16;
wherein R1 is the same or different moiety and is a compound of formula VII:

L is a linker, wherein the linker is a C8 to C20 alkyl, alkylamino, alkenyl, alkynyl, hydroxyalkyl, alkoxy, dialkylamino thioalkyl, thioalkenyl, thioalkynyl, aryloxy, acyloxy, thioacyl, amido, polyethylene glycol and sulphonamido, wherein each of alkyl or aryl moiety may be unsubstituted or substituted with one or more substituents selected from the group consisting of halo, hydroxy, carboxy, phosphoryl, phosphonyl, phosphono C1-C6 alkyl, carboxy C1-C6 alkyl, dicarboxy C1-C6 alkyl, dicarboxy halo C1-C6 alkyl, sulfonyl, cyano, nitro, alkoxy, alkylthio, acyl, acyloxy, thioacyl, acylthio, aryloxy, amino, alkylamino, dialkylamino, trialkylamino, arylalkylamino, guanidino, aldehydo, ureido, and aminocarbonyl; and
alternatively, R1 is a peptide ligand to an enzyme or endothelial receptor, and wherein R2 is a chelating moiety, a fluorescent dye or H,
wherein when R2 is a chelating moiety, it can be bound to a metal ion useful in imaging, or as a cytotoxic moiety;
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

US Pat. No. 10,653,805

COMPOSITIONS AND METHODS FOR IN VIVO IMAGING

The General Hospital Corp...

1. A compound of formula:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,653,798

ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, METHODS OF MAKING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES, AND METHOD OF USING ELECTROACTIVE SUPRAMOLECULAR POLYMERIC ASSEMBLIES

University of Florida Res...

1. An electroactive supramolecular polymeric assembly, comprising: an electroactive ABA block copolymer, where A is a non-electroactive polymer and B is an electroactive polymer, wherein the polymer has the following structure:
where n is 2 to 1000 and m+p is 2 to 2000.

US Pat. No. 10,653,796

LIPOSOMES CONTAINING CELL PENETRATING PEPTIDES AND TETRAETHERLIPIDS FOR THE ORAL DELIVERY OF MACROMOLECULES

1. A liposomal oral composition comprising liposomes, said liposomes comprising:(a) tetraether lipids (TELs), wherein the TEL is selected from the group consisting of glycerylcaldityltetraether (GCTE) and diglyceryltetraether (DGTE) comprising an average number of four to six cyclopentyl rings and TELs comprising three to five pentyl rings, and combinations thereof;
(b) cell penetrating peptides (CPPs),
wherein said CPPs are attached to a lipid of the liposome's lipid double layer, and wherein the liposomes have a positive zeta potential and;
(c) a therapeutic and/or diagnostic agent selected from the group consisting of peptidic macromolecules, proteins and antibodies.

US Pat. No. 10,653,795

HYDROGEL-LINKED PRODRUGS RELEASING TAGGED DRUGS

1. A process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, comprising the steps of:(a) providing a mixture comprising:
(a-i) at least one backbone reagent, wherein the at least one backbone reagent has a molecular weight ranging from 1 to 100 kDa, and comprises at least three functional groups Ax0, wherein each Ax0 is an amine (—NH2 or —NH—), a hydroxyl (—OH), a carboxyl (—COOH), or an activated carboxyl of the formula —COY1, wherein Y1 is selected from formulas (f-i) to (f-vi):

wherein;
the dashed lines indicate attachment to the rest of the molecule;
b is 1, 2, 3, or 4; and
XH is Cl, Br, I, or F; and
(a-ii) at least one crosslinker reagent, wherein the at least one crosslinker reagent has a molecular weight ranging from 0.2 to 40 kDa and comprises at least two functional end groups selected from the group consisting of activated ester groups, activated carbamate groups, activated carbonate groups, activated thiocarbonate groups, and amine groups;
wherein a weight ratio of the at least one backbone reagent to the at least one crosslinker reagent is from 1:99 to 99:1; and
wherein the molar ratio of Ax0 to functional end groups is >1;
(b) polymerizing the mixture of step (a) to a hydrogel;
(c) optionally covalently conjugating a spacer reagent of formula (VI) to Ax0 of the hydrogel from step (b), where the formula (VI) is:
Ax1-SP2-Ax2  (VI);
wherein
SP2 is C1-50 alkyl, C2-50 alkenyl, or C2-50 alkynyl, which C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl is optionally interrupted by one or more group(s) selected from the group consisting of —NH—, —N(C1-4 alkyl)-, —O—, —S—, —C(O)—, —C(O)NH—, —C(O)N(C1-4 alkyl)-, —O—C(O)—, —S(O)—, —S(O)2—, 4- to 7-membered heterocyclyl, phenyl, and naphthyl;
Ax1 is a functional group for reaction with Ax0 of the hydrogel; and
Ax2 is a functional group; and
(d) covalently conjugating;
(d-i) a reversible prodrug linker reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, resulting in a reversible prodrug linker moiety conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a drug to said reversible prodrug linker moiety resulting in a reversible prodrug linker moiety-biologically active moiety conjugate conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a tag reagent to the biologically active moiety resulting in a reversible prodrug linker moiety-biologically active moiety-tag moiety conjugate conjugated to the hydrogel of step (b) or (c); or
(d-ii) a reversible prodrug linker reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, resulting in a reversible prodrug linker moiety conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a biologically active moiety-tag moiety conjugate reagent to said reversible prodrug linker moiety through a functional group of the biologically active moiety resulting in a reversible prodrug linker moiety-biologically active moiety-tag moiety conjugate conjugated to the hydrogel of step (b) or (c); or
(d-iii) a reversible prodrug linker moiety-biologically active moiety conjugate reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, through a functional group of the reversible prodrug linker moiety, followed by covalently conjugating a tag reagent to said biologically active moiety; or
(d-iv) a reversible prodrug linker moiety-biologically active moiety-tag moiety conjugate reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, through a functional group of the reversible prodrug linker moiety; or
(d-v) a reversible prodrug linker reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, resulting in a reversible prodrug linker moiety conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a tag reagent to said reversible prodrug linker moiety resulting in a reversible prodrug linker moiety-tag moiety conjugate conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a drug to said tag moiety resulting in a reversible prodrug linker moiety-tag moiety-biologically active moiety conjugate conjugated to the hydrogel of step (b) or (c); or
(d-vi) a reversible prodrug linker reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, resulting in a reversible prodrug linker moiety conjugated to the hydrogel of step (b) or (c), followed by covalently conjugating a tag moiety-biologically active moiety conjugate reagent to said reversible prodrug linker moiety through a functional group of the tag moiety;
(d-vii) a reversible prodrug linker moiety-tag moiety conjugate reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, through a functional group of the reversible prodrug linker moiety, followed by covalently conjugating a drug to said tag moiety; or
(d-viii) a reversible prodrug linker moiety-tag moiety-biologically active moiety conjugate reagent to Ax0 or Ax2 of the hydrogel of step (b) or (c), respectively, through a functional group of the reversible prodrug linker moiety;
wherein the linkage between the reversible prodrug linker moiety and the biologically active moiety in the prodrug according to (d-i), (d-ii), (d-iii), and (d-iv) and the linkage between the reversible prodrug linker moiety and the tag moiety in the prodrug according to (d-v), (d-vi), (d-vii), and (d-viii) is reversible;
wherein the biologically active moiety is a small molecule drug in bound form having a molecular weight of between 50 Da and 1 kDa, a peptide drug in bound form, a protein drug in bound form, or an oligonucleotide drug in bound form; and
wherein the tag moiety is a polymer with a molecular weight ranging from 0.5 to 50 kDa.

US Pat. No. 10,653,794

CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION

Pfizer Inc., New York, N...

1. A method of producing an antibody drug conjugate (ADC) comprising the steps:(a) producing a capped antibody in a cell culture, wherein one or more unpaired cysteine residues on said antibody are covalently bonded through sulfur bonds to one or more predetermined capping moieties, wherein said predetermined capping moieties are selected from the group consisting of 5-thio-2-nitrobenzoic acid (TNB), 2-mercaptopyridine and dithiodipyridine (DTDP);
(b) exposing said capped antibody to a reducing agent capable of removing said capping moieties from said antibody without reducing antibody inter-chain sulfur bonds, wherein said reducing agent is tris (3-sulfophenyl) phosphine (TSPP):
and(c) without introducing an oxidizing agent, conjugating one or more reduced sulfur bonds on said antibody to a payload via a linking moiety, wherein said payload is an auristatin, a spliceostatin or a calicheamicin.

US Pat. No. 10,653,790

COMPOSITIONS AND METHODS RELATED TO SCAVENGER PARTICLES

NaNotics, LLC, Mill Vall...

1. A particle comprising a first plurality of reactive groups, wherein:each reactive group of the first plurality of reactive groups can selectively react with a first agent comprising a first predetermined functional group;
each reactive group of the first plurality of reactive groups is disposed on the particle such that after the first agent is linked to that reactive group through the first predetermined functional group, the first agent has a reduced ability to bind to a molecule on the surface of a cell;
the particle comprises a plurality of coating molecules, wherein the plurality of coating molecules comprises a polymer; and
the longest dimension of the particle is about 50 nm to about 5 ?m.

US Pat. No. 10,653,788

CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS

QuiaPEG Pharmaceuticals A...

1. A conjugate, or a pharmaceutically acceptable salt thereof, comprising a compound of formula (11):
or a salt form thereof, wherein:
polymer is a linear, water-soluble, non-peptidic, and non-nucleotidic polymer backbone, wherein M2 and the phosphonate-derived functional group are bonded at a different terminus of said polymer;
E and E1 are independently O or S;
K is selected from the group consisting of: alkylene, alkyleneoxyalkylene, and oligomeric alkyleneoxyalkylene;
G is selected from the group consisting of: hydrogen, alkoxy, and a hydrophobic separation handle;
Z1 and Z2 are independently selected from O and NH, wherein only one of Z1 and Z2 can be NH;
L is selected from the group consisting of: a divalent radical of nucleoside, alkylene, alkyleneoxyalkylene, oligomeric alkyleneoxyalkylene, and unsubstituted and substituted arylene;
L2 is a covalent linking moiety between L on the polymer backbone and B;
L4 is a covalent linking moiety between L on the polymer backbone and B1; and
B and B1 are independently a TNF inhibitor, a derivative of a TNF inhibitor, a biologic other than a TNF inhibitor, a drug, a detectable group, a separation moiety, wherein at least one of B and B1 is a TNF inhibitor or a derivative of a TNF inhibitor.

US Pat. No. 10,653,786

SILK MICROSPHERES AND METHODS FOR SURFACE LUBRICATION

TRUSTEES OF TUFTS COLLEGE...

1. A lubricated microsphere comprising:a silk fibroin microsphere comprising
one or more pores having a pore size range of 1 nm to 100 ?m,
wherein the silk fibroin is free of lipid; and
a phospholipid coating on a surface of the silk fibroin microsphere,
wherein when the lubricated microsphere is under a cyclic shear loading pressure of at least 0.08 MPa for at least a week, the lubricated microsphere resist degradation, and
wherein the lubricated microsphere is characterized by a static friction coefficient of less than 0.1, as determined by a friction test against a silica surface.

US Pat. No. 10,653,780

AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS

THE UNIVERSITY OF BRITISH...

1. A lipid particle comprising an amino lipid having the structureor a salt of thereof.

US Pat. No. 10,653,776

COMPOSITIONS AND METHODS FOR REDUCING OVERDOSE

Intellipharmaceutics Corp...

1. A method of inhibiting or preventing drug overdose in a patient, comprising administering to the patient a unit dose formulation comprising:at least one active substance, wherein release of said at least one active substance is inhibited when the number of unit dosage forms ingested exceeds a predetermined number;
at least one actuator; and
at least one regulator surrounding said at least one active substance and said at least one actuator,
whereby when the unit dose formulation is exposed to a fluid media having a process variable, said process variable being pH, said at least one regulator is capable of adjusting the pH to inhibit the release of said at least one active substance via said at least one actuator, when the number of unit dosage forms exceeds the predetermined number.

US Pat. No. 10,653,774

COMPOSITIONS AND METHODS FOR ACTIVATING “STIMULATOR OF INTERFERON GENE”-DEPENDENT SIGNALLING

ADURO BIOTECH, INC., Ber...

1. A method of treating cancer in a subject in need thereof, comprising:administering to the subject one or both of a CTLA-4 pathway antagonist selected from the group consisting of Ipilimumab and tremelimumab and a PD-1 pathway antagonist selected from the group consisting of MK-3475, CT-011, AMP-224, and MDX-1106; and
administering to the subject a compound having the formula:

where R1 and R2 are each H,
or a pharmaceutically acceptable salt thereof, wherein the administration of the compound is directly into a tumor mass.

US Pat. No. 10,653,743

METHODS FOR THE TREATMENT OF DEPRESSION AND ANXIETY BY A MELANOCORTIN 5 RECEPTOR ANTAGONIST, PG-20N

ARIZONA BOARD OF REGENTS ...

1. A method of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment, said method comprising administering to the subject a therapeutically effective amount of a composition comprising:in a pharmaceutically acceptable carrier.

US Pat. No. 10,653,737

SYNERGISTIC NUTRITIONAL COMPOSITIONS FOR PAIN MANAGEMENT

Celagenex Research (India...

1. A synergistic nutritional composition(s) for treating neuropathic pain comprising a therapeutic exogenous blend of palmitoylethanolamide (PEA) and standardized red spinach extract with enriched nitrate content, wherein the PEA and the standardized red spinach extract with enriched nitrate content are present in the ratio of 1:0.1 to 1:5; and PEA and nitrate of the standardized red spinach extract are present in the ratio of 1:0.01 to 1:0.5, along with pharmaceutically acceptable excipients.

US Pat. No. 10,653,732

COMPOSITION FOR STIMULATING INSULIN SECRETION FROM CELLS AND USE THEREOF

KOREA INSTITUTE OF SCIENC...

1. A method of stimulating insulin secretion from cells, the method comprising contacting a composition or an extract with cells,wherein the composition comprises any stereoisomer selected from the group consisting of Formulae I, II, and III, a solvate or hydrate thereof, or a mixture thereof, or a physiologically acceptable salt thereof:

wherein, in Formula I, II, and III, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are each independently H or (C1-C6)-alkyl, and
the extract is a Hypoxylon sp. mushroom extract comprising any stereoisomer selected from the group consisting of Formulae I, II, and III, a solvate or hydrate thereof, or a mixture thereof, or a physiologically acceptable salt thereof:

wherein, in Formula I, II, and III, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12 are each independently H or (C1- C6) alkyl.

US Pat. No. 10,653,719

STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USE

EXELA PHARMA SCIENCES, LL...

1. A solution of L-cysteine comprising,a pharmaceutically acceptable carrier,
about 50 mg/mL of L-cysteine hydrochloride monohydrate, or equivalent amount of a pharmaceutically acceptable L-cysteine or a salt or hydrate thereof,
less than about 150 ppb of aluminum,
a pH from about 1.0 to about 2.5, and
wherein the solution is substantially free of visually detectable particulate matter and suitable for use as an additive in a parenteral nutrition composition for administration to an individual.

US Pat. No. 10,653,717

ANTIBIOTIC COMPOSITIONS

1. A pharmaceutical antibiotic composition in a unit dosage form, wherein the pharmaceutical antibiotic composition comprises a silver-containing agent and an organoselenium agent, and wherein the organoselenium agent comprises an ebselen in an amount effective for treating a bacterial infection.

US Pat. No. 10,653,713

METHODS FOR DISTRIBUTING AGENTS TO AREAS OF BRAIN

Medtronic, Inc., Minneap...

1. A method comprising:selecting a subject for which delivery of a therapeutic or diagnostic molecule to cerebrospinal fluid (CSF) of a brain is desired; and
administering a liquid formulation comprising the molecule to an CSF-containing intrathecal space of the subject at a flow rate of less than 500 microliters per hour, wherein the liquid formulation is administered for a period of time sufficient to reach a steady state concentration in CSF of the brain, and wherein the molecular weight of the molecule is less than 5 kDa, between 15 kDa and 200 kDa, greater than 200 kDa, or a polypeptide or antisense DNA having a molecular weight of between 5 kDa and 15 kDa, and wherein the molecule is generally distributed throughout at least most of the CSF of the brain at therapeutically or diagnostically effective concentrations.

US Pat. No. 10,653,711

6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

Janssen Pharmaceutica NV,...

1. A compound of Formula (I)
wherein
R1 represents hydrogen or —C(?O)—C1-4alkyl;
R2 represents hydrogen or —C(?O)—C1-4alkyl;
Y represents —CH2— or —CF2—;
Z represents —CH2—, —X—CR5aR5b—, —CR5c?CR5d—, —CR5eR5g—CR5fR5h—, —C?C—, —O—, or —CR5aR5b—X—;
R5a, R5b, R5c, R5d, R5e, R5f, R5g, and R5h each independently represent hydrogen or C1-4alkyl;
X represents —O—, —S—, or —NR11—;
R11 represents hydrogen, C1-4alkyl, or C1-4alkyl substituted with one substituent selected from the group consisting of —OH, —O—C1-4alkyl, R12, —NH2, —NH—C1-4alkyl, and —N(C1-4alkyl)2;
R12 represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via the ring nitrogen atom;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,

wherein at least 1 ring carbon atom of ring B is replaced by a nitrogen atom;
wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, —OH, —NH2, —NH—C1-4alkyl, —N(C1-4alkyl)2, —NHR10d, —NR10cR10d, cyano, —CF3, —C(?O)—NH2, —C(?O)—NH—C1-4alkyl, —C(?O)—C1-4alkyl, C1-4alkyloxy, —C(?O)—O—C1-4alkyl, C3-6cycloalkyl, —O—C3-6cycloalkyl, —NH—C3-6cycloalkyl, —N(C3-6cycloalkyl)2, C2-6alkenyl, C1-4alkyl substituted with one C1-4alkyloxy, and C1-4alkyl optionally substituted with one —NR10aR10b;
R10a and R10b each independently represent hydrogen or C1-4alkyl;
R10c and R10d each independently represent C3-6cycloalkyl; R13; R14; C3-6cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C1-4alkyl; C1-4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, —OH and —O—C1-4alkyl; or C1-4alkyl substituted with one substituent selected from the group consisting of C3-6cycloalkyl, R13 and R14;
R13 represents a monocyclic aromatic ring selected from the group consisting of pyrrolyl, pyridinyl and furanyl; or a bicyclic fused aromatic ring selected from the group consisting of indolyl and quinolinyl;
said monocyclic aromatic ring or bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C1-4alkyl;
R14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), and (a-4):

wherein R3a, R3c, and R3d each independently represent hydrogen, halo, —NR7aR7b,
C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl, —OH, or —O—C1-4alkyl;
R7a represents hydrogen;
R7b represents hydrogen, C3-6cycloalkyl, or C1-4alkyl;
R4a, R4c, R4d, R4e and R4f each independently represent hydrogen, halo,
—NR8aR8b, or C1-4alkyl;
R8a and R8b each independently represent hydrogen or C1-4alkyl;
Q1 represents N or CR6a;
Q2 represents N or CR6b;
Q8 represents N or CR6g;
Q9 represents N or CR6h;
Q5 represents CR3d; Q6 represents N; and Q7 represents CR4f; or
Q5 represents CR3d; Q6 represents CR4e; and Q7 represents N; or
Q5 represents N; Q6 represents CR4e; and Q7 represents CR4f; or
Q5 represents N; Q6 represents CR4e; and Q7 represents N; or
Q5 represents N; Q6 represents N; and Q7 represents CR4f; or
Q5 represents N; Q6 represents N; and Q7 represents N;
R6a, R6b, R6e, R6f, R6g, and R6h each independently represent hydrogen, halogen, C1-4 alkyl, —NR9aR9b, or C1-4alkyl substituted with one, two or three halo atoms;
R9a and R9b each independently represent hydrogen or C1-4alkyl;
or a pharmaceutically acceptable addition salt thereof.

US Pat. No. 10,653,710

COMBINATION THERAPY FOR TREATING MALIGNANCIES

Agios Pharmaceuticals, In...

1. A method of treating acute myelogenous leukemia (AML) characterized by the presence of a mutant allele of IDH1, comprising administering to a subject in need thereof a mutant isocitrate dehydrogenase 1 (IDH1) inhibitor and azacitidine, wherein the mutant IDH1 inhibitor is (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, having the following formula:or a pharmaceutically acceptable salt thereof (COMPOUND 2), and wherein the mutant allele of IDH1 has a mutation selected from R132H, R132C, R132L, R132V, R132S and R132GF.

US Pat. No. 10,653,709

METHODS OF FOLDING A GRAFT COPOLYMER WITH DUAL ANTICANCER DRUGS AND RELATED APPLICATIONS

North Carolina State Univ...

1. A graft copolymer drug conjugate, wherein the graft copolymer drug conjugate has the formula:wherein:A is a trivalent moiety;
B comprises a hydrophilic polymeric moiety;
X is a divalent moiety comprising a covalently attached first therapeutic agent, wherein X is derived from a monomer that comprises a moiety that can undergo ring opening polymerization and wherein said monomer comprises the covalently attached first therapeutic agent;
n is an integer between 4 and 25;
m is an integer between 5 and 30; and
each of R1, R2, and R3 is a monovalent moiety.

US Pat. No. 10,653,705

APPLICATIONS FOR ESTRONE IN PREPARING ANTI-OVARIAN CANCER AND/OR BREAST CANCER PRODUCTS

SHANGHAI JIAO TONG UNIVER...

1. A method for treating ovarian cancer comprising administering an effective amount of estrone to a subject in need thereof.

US Pat. No. 10,653,699

CONTROLLED-RELEASE TOZADENANT FORMULATIONS

Biotie Therapies, Inc., ...

1. A composition comprising tozadenant, at least one cellulose ether, and one or more pharmaceutically acceptable excipients,wherein the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight,
wherein the cellulose ether is present in an amount sufficient to provide:
not less than about 10% and not more than about 30% tozadenant dissolution over a 2-hour test period,
not less than about 55% tozadenant dissolution over a 10-hour test period, and
not less than about 80% tozadenant dissolution over a 16-hour test period;
wherein the cellulose ether is present in an amount ranging from about 10% (w/w) to about 30% (w/w) based on the total composition weight; and
wherein the one or more pharmaceutically acceptable excipients comprise a glidant or anti-adherent in an amount ranging from about 0.5% to 10% based on the total composition weight.

US Pat. No. 10,653,696

USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

Pharmacyclics LLC, Sunny...

1. A method for treating mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma comprising orally administering to the individual a dose of 560 mg of an inhibitor of Bruton's tyrosine kinase (Btk) on a continuous once-daily regimen until progression of the mantle cell lymphoma or unacceptable toxicity; andlymphocytosis is not considered progression of the mantle cell lymphoma,
wherein the inhibitor of Btk has
the structure:
wherein the individual achieves a complete response.

US Pat. No. 10,653,694

CYTOTOXIC COMPOUNDS WHICH ARE INHIBITORS OF THE POLYMERISATION OF TUBULIN

CENTRE NATIONAL DE LA REC...

11. A pharmaceutical composition comprising a compound according to claim 1.

US Pat. No. 10,653,692

CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES

DEZIMA PHARMA BV, (NL)

1. A method of treating a subject suffering from or having an increased risk for cardiovascular diseases, the method comprising administering to said subject in need thereof an effective dosage amount of a compound of the formula A:
or a pharmaceutically acceptable salt thereof, wherein the effective dosage amount of said Compound A to be administered to said subject is 1 mg, 2.5 mg, 5 mg, 10 mg, or 25 mg daily, wherein said daily administration decreases LDL-C concentrations in a dose-dependent manner with maximum decreases from baseline of approximately 40% to 53% following said 1 mg, 2.5 mg, 5 mg, 10 mg, or 25 mg of said daily administration of compound A or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,653,691

METHOD OF PROMOTING REMYELINATION

Case Western Reserve Univ...

1. A method of treating a myelination-related disorder characterized by chronic progressive demyelination in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a primary 1,3-diazole compound having the formula:or a pharmaceutically acceptable salt thereof; wherein R2, R3, R4, R5, R6, R7, and R8 are each individually one or more substituted or unsubstituted groups selected from:

US Pat. No. 10,653,690

PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY

OREXO AB, Uppsala (SE)

1. A solid pharmaceutical composition in the form of a spray-dried powder that is suitable for nasal delivery of naloxone or a pharmaceutically acceptable salt thereof to treat opioid overdose, comprising:a pharmacologically-effective amount of naloxone or a pharmaceutically acceptable salt thereof;
a C8-22 saturated or unsaturated fatty acid sucrose ester; and
a pharmaceutically-acceptable carrier material comprising a combination of:
(i) a disaccharide selected from the group consisting of maltitol, trehalose, sucralose, sucrose, isomalt, maltose, and lactose; and
(ii) a dextrin;
wherein the naloxone or pharmaceutically acceptable salt thereof is less than about 15% chemically degraded after 3 months at 75% relative humidity and 40° C.

US Pat. No. 10,653,689

COMBINATION-BASED TREATMENT METHOD

Nektar Therapeutics, San...

1. A method of treating a patient having BRCA1-deficient breast cancer, the method comprising the steps of: (a) administering to the patient having BRCA1-deficient breast cancer, a PARP-inhibiting amount of rucaparib; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor having a structure:where each n is about 113;or pharmaceutically acceptable salts thereof.

US Pat. No. 10,653,688

6-(6-MEMBERED HETEROARYL AND ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Samumed, LLC, San Diego,...

1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:
wherein:
R1, R2, R4, and R5 are independently selected from the group consisting of H, F, and Cl;
R3 is selected from the group consisting of phenyl optionally substituted with 1-3 R7 and a 6-10-membered heteroaryl optionally substituted with 1-3 R8;
R6 is selected from the group consisting of —(C1-4 alkylene)p(5-10-membered)heteroaryl optionally substituted with 1-3 R9, —(C1-4 alkylene)pphenyl optionally substituted with 1-3 R25, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R10, —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R11, —(C1-4 alkylene)N(R12)(R13), —N(R14)(R15), —CF(C1-9 alkyl)2, —(C1-4 alkylene)pO(C1-9 alkyl), and —(C2-9 alkynyl) optionally substituted with one or more F and/or Cl; wherein each alkyl of —CF(C1-9 alkyl)2 is, independently, optionally substituted with one or more F and/or Cl; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R7 is selected from the group consisting of F, Cl, and —N(R16)2;
R8 is selected from the group consisting of F, Cl, unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —CN, —N(R17)(R18), —(C1-4 alkylene)pX1R19, —C(?O)N(R20)2, and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R21; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R9 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —X2R22, —C(?O)N(R23)2, —(C1-4 alkylene)pN(R24)2, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R25, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R26; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R10 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —(C1-4 alkylene)pOR27, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R28, —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29, —C(?O)(R30), —(C1-4 alkylene)pC(?O)OR30, —N(R20)2, —(C1-4 alkylene)phenyl optionally substituted with one or more F and/or Cl, —(C1-4 alkylene)p(5-10-membered)heteroaryl optionally substituted with one or more F and/or Cl, and —SO2(R31); wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
alternatively, if two R10 are attached to the same carbon atom can together represent ?O to form a carbonyl group;
each R11 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —(C1-4 alkylene)pOR27, —N(R20)2, —C(?O)(R30), —C(?O)OR30, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R28, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R12 is attached to the nitrogen and is selected from the group consisting of H, unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R32, and 3-7-membered -carbocyclyl optionally substituted with 1-3 R33; wherein —(C1-4 alkylene) is, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R13 is attached to the nitrogen and is selected from the group consisting of unsubstituted —(C1-9 alkyl), unsubstituted —(C2-9 alkenyl), unsubstituted —(C2-9 alkynyl), unsubstituted —(C1-9 chloroalkyl), unsubstituted —(C1-9 fluoroalkyl), —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R32, and 3-7-membered -carbocyclyl optionally substituted with 1-3 R33; wherein —(C1-4 alkylene) is, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R14 is attached to the nitrogen and selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), and unsubstituted —(C1-5 fluoroalkyl);
R15 is attached to the nitrogen and is selected from the group consisting of —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R32, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R33; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R16 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —(C1-4 alkylene)phenyl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), —(C1-4 alkylene)p(5-10-membered)heteroaryl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
alternatively, two adjacent R16 are taken together to form a 3-10-membered -heterocyclyl ring optionally substituted with 1-3 R32;
R17 is attached to the nitrogen and is selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), and unsubstituted —(C1-5 fluoroalkyl);
R18 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), unsubstituted —(C1-5 haloalkyl), —(C?O)R34, and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R19 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein —(C1-4 alkylene) is optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R20 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), and unsubstituted —(C1-5 fluoroalkyl);
each R21 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —N(R20)2, —CN, and —OH;
each R22 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —(C1-4 alkylene)N(R34)2, —(C1-4 alkylene)phenyl optionally substituted with 1-5 R35, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R36, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R23 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), and unsubstituted —(C1-5 fluoroalkyl);
each R24 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —(C1-4 alkylene)N(R34)2; wherein —(C1-4 alkylene) is optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R25 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —CN, —C(?O)R37, —N(R38)2, —(C1-4 alkylene)pOR27, —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with 1-3 R32, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R26; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl;
each R26 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —CN;
each R27 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29, and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R28 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —CN, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R29 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —CN;
R30 is selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —(C1-4 alkylene)phenyl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), —(C1-4 alkylene)p(5-10-membered)heteroaryl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R31 is selected from the group consisting of unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —(C1-4 alkylene)phenyl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), —(C1-4 alkylene)p(5-10-membered)heteroaryl optionally substituted with one or more F and/or Cl or unsubstituted —(C1-5 alkyl), and —(C1-4 alkylene)p(3-10-membered)heterocyclyl optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-5 alkyl); wherein —(C1-4 alkylene) is, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R32 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R33 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
R34 is attached to the nitrogen and is selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), and unsubstituted —(C1-5 fluoroalkyl);
each R35 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), and —CN;
each R36 is independently selected from the group consisting of F, Cl, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 chloroalkyl), unsubstituted —(C1-5 fluoroalkyl), —CN, —OH, —C(?O)R37, —N(R38)2, and —(C1-4 alkylene)p(3-7-membered)carbocyclyl optionally substituted with 1-3 R29; wherein each —(C1-4 alkylene) is, independently, optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R37 is a 5-10-membered heteroaryl optionally substituted with 1-6 R39;
each R38 is independently selected from the group consisting of H, unsubstituted —(C1-5 alkyl), unsubstituted —(C2-5 alkenyl), unsubstituted —(C2-5 alkynyl), unsubstituted —(C1-5 haloalkyl), and —(C1-4 alkylene)N(R34)2; wherein —(C1-4 alkylene) is optionally substituted with one or more F and/or Cl or one or more unsubstituted —(C1-3 alkyl);
each R39 is a 3-10-membered -heterocyclyl optionally substituted with 1-3 R29;
each X1 is selected from the group consisting of O and S;
each X2 is selected from the group consisting of O, S, and NR34;
each p is independently 0 or 1; and
with the proviso that Formula I is not a structure selected from the group consisting of:

US Pat. No. 10,653,684

ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY

Bayer Healthcare LLC, Wh...

1. A method of blocking tumor angiogenesis in a human or other mammal comprising administering to a human or other mammal with a tumor of the liver an effective amount of the compound N-(4-chloro-3-(trifluoromethyl)phenyl)-N?-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea of the formula below or a pharmaceutically acceptable salt thereofwherein the tumor of the liver is characterized by abnormal angiogenesis or hyperpermiability processes, which are mediated by KDR(VEGFR-2).

US Pat. No. 10,653,682

OXADIAZOLES AND THIADIAZOLES AS TGF-? INHIBITORS

Southern Research Institu...

1. A compound having a structure represented by a formula selected from:
wherein n is selected from 1, 2, 3, and 4;
wherein X is selected from O and S;
wherein R1 is selected from C1-C8 alkyl and Cy1;
wherein Cy1, when present, is selected from C3-C8 cycloalkyl and aryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein R2 is selected from hydrogen, C1-C4 alkyl, and amine protecting group;
wherein R3 is selected from NR20aR20b, NHCOR21, NHPG1, and Ar1;
wherein PG1 is an amine protecting group;
wherein each of R20a and R20b, when present, is independently selected from hydrogen, C1-C4 alkyl, Cy2, and amine protecting group;
wherein Cy2, when present, is selected from C3-C8 cycloalkyl and aryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein R21, when present, is selected from C1-C4 alkyl, cycloalkyl, and heterocycloalkyl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein Ar1, when present, is selected from aryl and heteroaryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —CN, C1-C4 alkyl, C, 1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, —(CH2)mNH2, —(CH2)m(C1-C4 alkylamino), —(CH2)m[(C1-C4)(C1-C4) dialkylamino], —(CH2)mNH(C?O)(C1-C4 alkyl), —(CH2)mN(C1-C4 alkyl)(C?O)(C1-C4 alkyl), and Cy5;
wherein m is selected from 0 and 1;
wherein Cy5, when present, is selected from C3-C8 cycloalkyl and aryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein each of R4a and R4b is independently selected from hydrogen and C1-C4 alkyl;
or wherein each of R4a and R4b are optionally covalently bonded together and, together with the intermediate atoms, comprise a 3- to 7-membered cycloalkyl substituted with 0-4 non-hydrogen groups independently selected from halogen, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
wherein each of R5a and R5b is independently selected from hydrogen, C1-C4 alkyl, and Cy3; and
wherein Cy3, when present, is selected from C3-C8 cycloalkyl and aryl and is substituted with 0-4 non-hydrogen groups independently selected from halogen, —NH2, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,653,681

ANALGESIC COMPOUNDS

Recurium IP Holdings, LLC...

1. A method for reducing or at least partially preventing pain or fever comprising administering an effective amount of a medicament comprising any of the compound selected from the group consisting of:ora pharmaceutically acceptable salt of any of the foregoing.

US Pat. No. 10,653,680

TREATMENT OF IMPULSIVITY-RELATED DISORDERS

OXFORD UNIVERSITY INNOVAT...

1. A method of treating a condition selected from a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self-harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or Attention Deficit Hyperactivity Disorder (ADHD), comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to a human subject in need thereof, wherein Formula I is;
wherein:
E is S or Se;
R1 and R2 are optional substituents, and are at each occurrence independently selected from:
(1) a halogen;
(2) C1-C4 alkyl, optionally substituted with one or more halogen atoms; and
(3) C1-C4 alkoxy; optionally substituted with one or more halogen atoms;
m is an integer in the range of from 0 to 5; and
n is an integer in the range of from 0 to 4.

US Pat. No. 10,653,677

1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE

Incyte Holdings Corporati...

1. A method of inhibiting or ameliorating cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound selected from a compound of Formula I and a compound of Formula F28:or a pharmaceutically acceptable salt thereof, and a chemotherapeutic agent; wherein:R1 is NH2 or CH3;
R2 is Cl, Br, CF3, CH3, or CN;
R3 is H or F;
R4 is F, Cl, Br, or I; and
n is 1 or 2.

US Pat. No. 10,653,676

SMALL MOLECULE INHIBITORS OF USP1 DEUBIQUITINATING ENZYME ACTIVITY

Dana-Farber Cancer Instit...

1. A method for treating a subject having a breast cancer or an ovarian cancer, comprising:administering to a subject having breast cancer or ovarian cancer in need of such treatment a small molecule inhibitor of ubiquitin specific protease 1 (USP1) according to Formula I:

wherein
X is O or S;
n is 0, 1, 2, 3, or 4;
each occurrence of R1 is independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORA; —C(?O)RA; —C(?O)N(RA)2; —CO2RA; —CN; —SCN; —SRA; —SORA; —SO2RA; —NO2; —N3; —N(RA)2; —NHC(?O)RA; —NRAC(?O)N(RA)2; —OC(?O)ORA; —OC(?O)RA; —OC(?O)N(RA)2; —NRAC(?O)ORA; or —C(RA)3; wherein each occurrence of RA is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;
R2 is hydrogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic, substituted or unsubstituted, heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORB; —C(?O)RB; —C(?O)N(RB)2; —SORB; —NHC(?O)RB; —NRBC(?O)N(RB)2; or —C(RB)3;
wherein each occurrence of RB is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety; and
wherein when R2 is substituted aliphatic, each substituent is independently selected from an aryl moiety, a heteroaryl moiety, an arylalkyl moiety, a heteroarylalkyl moiety, an alkoxy moiety, an aryloxy moiety, a heteroalkoxy moiety, a heteroaryloxy moiety, an alkylthio moiety, an arylthio moiety, a heteroalkylthio moiety, a heteroarylthio moiety, —F, —Cl, —Br, —I, —OH, —NO2, —CF3, —CH2CF3, —CHCl2, —CH2OH, —CH2CH2OH, —CH2NH2, —CH2SO2CH3, —C(O)Rx, —CO2(Rx), —CON(Rx)2, —OC(O)Rx, —OCO2Rx, —OCON(Rx)2, —N(Rx)2, —S(O)2Rx, —NRx(CO)Rx, wherein each occurrence of Rx is independently an aliphatic moiety, a heteroaliphatic moiety, an aryl moiety, a heteroaryl moiety, an arylalkyl moiety, or a heteroalkyl moiety;
or a pharmaceutically acceptable salt thereof,
in an amount effective to treat the breast cancer or the ovarian cancer.

US Pat. No. 10,653,675

USE OF ISOXAZOLINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF ARTHROPOD INFESTATIONS IN POULTRY

Intervet Inc., Madison, ...

1. A method of preventing or treating an infestations of a laying hen by a temporary parasitic arthropod comprising administering via the drinking water an effective amount of an isoxazoline compound of formula (I)
Wherein
R1=halogen, CF3, OCF3, CN,
n=integer from 0 to 3
R2=C1-C3-haloalkyl
T=5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
or is selected from

wherein in T-1, T-3 and T-4 the radical Y is hydrogen, halogen, methyl, halomethyl, ethyl, haloethyl;
Y=methyl, halomethyl, halogen, CN, NO2, NH2—C?S, or two adjacent radicals Y form together a chain;
Q=X—NR3R4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
X=CH2, CH(CH3), CH(CN), CO, CS,
R3 =hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl,methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,

wherein ZA=hydrogen, halogen, cyano, halomethyl (CF3);
R4=hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
or R3 and R4 together form a substituent selected from the group consisting of:

or a salt or solvate thereof;
wherein the effective dose of the isoxazoline compound is administered via the drinking water in two or three separate dosages approximately 7 days apart;
wherein the temporary parasitic arthropod infestation is an infestation by Dermanyssus spp. and/or Ornithonyssus spp. mites; and
wherein the effective amount is between 0.1 and 10 mg/kg body weight of animals treated.

US Pat. No. 10,653,674

MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN

VERSEON CORPORATION, Fre...

1. A compound with structure of the following formula:
or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof,
wherein:
L1 is —NR5—;
L2 is a bond;
L3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
L4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, —S—, —SO—, —SO2—, —O—, —NHSO2—, or —NR5—;
R1 is substituted alkyl, wherein any substituent group of said R1 substituted alkyl is selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R2 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted single ring aryl, wherein any substituent group of said R2 substituted alkyl, substituted heteroalkyl, or substituted single ring aryl is selected from the group consisting of —OH, —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, oxo, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted and unsubstituted heteroaryl;
R3 is substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when R3 is substituted heteroaryl, any substituent group of said R3 heteroaryl is selected from the group consisting of —NH2, —SH, —CN, —CF3, —NO2, halogen, —COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted and unsubstituted heteroaryl;
R4 is hydrogen, or substituted or unsubstituted methyl; and
R5 is hydrogen or substituted or unsubstituted alkyl.

US Pat. No. 10,653,673

SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

Janssen Pharmaceutica NV,...

1. A substituted imidazole selected from the group consisting of:a compound according to structure 1

wherein structure 1 is 4-[2-(2-Methoxyphenyl)-4-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-imidazol-1-yl]-benzonitrile,
a compound according to structure 11

wherein structure 11 is 3-[1-(4-Chlorophenyl)-4-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-imidazol-2-yl]-2-methoxypyridine,
a compound according to structure 38

wherein structure 38 is 1-(4-Chlorophenyl)-2-(2-methoxyphenyl)-4-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-imidazole,
a compound according to structure 51,

wherein structure 51 is 3-[1-(4-Chlorophenyl)-4-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-imidazol-2-yl]-2-ethoxypyridine,
a compound according to structure 92

wherein structure 92 is 3-[5-Chloro-1-(4-fluorophenyl)-4-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-imidazol-2-yl]-2-methoxypyridine,
a compound according to structure 102

wherein structure 102 is 4-[1-(4-Chlorophenyl)-2-(2-methoxyphenyl)-1H-imidazol-4-yl]-2,2,6,6-tetramethyltetrahydro-2H-pyran-4-ol, and
a compound according to structure 111
wherein structure 111 is 4-[1-(3-Chloro-4-fluorophenyl)-2-(2-methoxyphenyl)-1H-imidazol-4-yl]-2, 2,6,6-tetramethyltetrahydro-2H-pyran-4-ol,and enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

US Pat. No. 10,653,672

MYOGENESIS PROMOTOR, MUSCLE ATROPHY INHIBITOR, MEDICAL COMPOSITION AND TAZ ACTIVATOR

National University Corpo...

1. A myogenesis promotor, comprising a compound selected from the following as an active ingredient:

US Pat. No. 10,653,670

USE OF INDOLE COMPOUNDS FOR FAT REDUCTION AND SKIN AND SOFT TISSUE TIGHTENING

Alevere Medical Corporati...

1. A method for non-surgical reduction or removal of one or more localized fat deposits in a subject having localized fat accumulation comprising administering to a target site in the fat deposit a compound of Formula (I-1), Formula (I-2), or Formula (I-3), wherein Formula (I-1) is represented by:
wherein
R1 is hydrogen or C1-6 alkyl;
R4, R5, R6, and R7 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, halogen, and —OCH2C6H5;
R2 and R3, together with the atoms they attach to, form
wherein R8, R10, and R11 are independently selected from hydrogen, halogen, —(CH2)x—C(O)—OC1-6 alkyl, —(CH2)xOH, —(CH2)x—CN, —OCH2C6H5, —OCOCH3, —(CH2)x—CONH2, —CHO, —(CH2)x—COOH, —(CH2)y—CO—COOH, —(CH2)y—C(H)(OH)—COOH, phenyl, and substituted phenyl; wherein the substituted phenyl is substituted with 1-4 substituents selected from hydroxyl, C1-6alkoxy, and C1-6alkyl;R9 is hydrogen or C1-6 alkyl;
x is a number from zero to six; and
y is zero;
or a pharmaceutically acceptable salt thereof;Formula (I-2) is represented by:
wherein
R1 is hydrogen or C1-6 alkyl;
R2 and R3 are independently hydrogen or C1-6 alkyl;
R4, R5, R6, and R7 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, —OCH2C6H5, halogen, —CHO, and —(CH2)x—COOH; and
x is a number from zero to six;
or a pharmaceutically acceptable salt thereof;
provided that at least one of R4, R5, R6, and R7 is —CHO or —(CH2)x—COOH; andFormula (I-3) is represented by:
wherein
R1 is hydrogen or C1-6 alkyl;
R2 is hydrogen or C1-6 alkyl;
R3 is —(CH2)x—COOH;
R4, R5, R6, and R7 are independently selected from hydrogen, C1-6alkyl, C1-6alkoxy, halogen, —(CH2)x—OH, and —OCH2C6H5; and
x is a number from zero to six;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,653,663

PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING TAXANE

DAE HWA PHARMA. CO., LTD....

1. A pharmaceutical composition for oral administration, consisting essentially of:(a) 0.8 to 1.2% by weight of paclitaxel or docetaxel,
(b) 25 to 30% by weight of a medium chain triglyceride,
(c) 50 to 55% by weight of an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, and
(d) 15 to 20% by weight of a surfactant selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymer, sorbitan ester, polyoxyethylene sorbitan, and polyoxyethylene ether,
wherein the pharmaceutical composition is in a clear solution form at room temperature, and
wherein the pharmaceutical composition is changed to a clear solution form when it is allowed to stand at room temperature after being stored at 4° C.

US Pat. No. 10,653,657

METHOD FOR TREATING HEMOLYTIC UREMIC SYNDROME

Enzychem Lifesciences Cor...

1. A method for treating hemolytic uremic syndrome (HUS), comprising administering to a patient in need thereof an effective amount of a compound of Formula 1:
wherein R1 and R2 are independently a fatty acid residue of 14 to 22 carbon atoms.

US Pat. No. 10,653,654

COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF

The General Hospital Corp...

1. A pharmaceutical dosage formulation for administration to a pre-obese, obese, or morbidly obese human comprising a compound having one of the following structures:
or a pharmaceutically acceptable salt thereof,
wherein the compound is present in the dosage formulation in a therapeutically effective amount to induce weight loss, reduce the body fat, reduce food intake, improve glucose homeostasis, or combinations thereof, in the pre-obese, obese, or morbidly obese human.

US Pat. No. 10,653,651

KIT FOR TREATING CANCER WITH LOW MOLECULAR WEIGHT COMPONENTS OF AURIN TRICARBOXYLIC ACID COMPLEX

Aurin Biotech Inc., Vanc...

1. A kit comprising an active agent selected from the group consisting of ATA, AQA, AHA, ATAC, and a pharmaceutically acceptable salt thereof, and a package insert comprising instructions for using the active agent to treat cancer in a subject, wherein the active agent excludes any components greater than or equal to 1 kilodalton in molecular weight, wherein the ATA is purified ATA, the AQA is purified AQA, and the AHA is purified AHA, and wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, B-cell carcinoma, colorectal adenocarcinoma, colorectal cancer, chronic myelogenous leukemia, bone osteosarcoma glioblastoma, pancreatic cancer, and lung cancer.

US Pat. No. 10,653,650

TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS

Io Therapeutics, Inc., H...

1. A method of treating a demyelination-related disorder, the method comprising the step of administering to an individual in need thereof a therapeutically effective amount of a selective RXR agonist with both remyelination promotion and immunomodulatory activities, wherein administration of the selective RXR agonist treats the demyelination-related disorder in the individual by both promoting remyelination of neurons and modulating the individual's immune system, wherein the selective RXR agonist is a compound having the structure of formula XII:
wherein R is H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt of the compound.

US Pat. No. 10,653,649

IMAGING COMPOSITION AND USES THEREOF

The University of Melbour...

1. A conjugate of:a compound of formula (I):

or a pharmaceutically acceptable salt thereof, and
a molecule to target a tissue or tumour,
wherein L is a leaving group selected from azide, halogen, cyanate and OR, wherein R is selected from C1 to C10 alkyl, C1 to C10 heteroalkyl, C2 to C10 alkene, C2 to C10 alkyne, and aryl, each of which is optionally substituted.

US Pat. No. 10,653,648

HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF

THE TRUSTEES OF COLUMBIA ...

1. A pharmaceutical composition comprising a HAT activator and a HDAC inhibitor, wherein the HAT activator is selected from the group consisting of:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,653,639

PHARMACEUTICAL FORMULATIONS CONTAINING CANNABIDIOL AND NICOTINE FOR TREATING SMOKELESS TOBACCO ADDICTION

CV Sciences, Inc., San D...

1. A method of treating smokeless tobacco addiction comprising transmucosally administering to an individual in need thereof a pharmaceutical composition comprising from about 1 to about 4 mg of nicotine, from about 8 to about 100 mg of cannabidiol, and a pharmaceutically acceptable vehicle therefor.

US Pat. No. 10,653,638

PIMARANE DITERPENOIDS FOR USE IN CANCER TREATMENT

University of South Carol...

1. A method for inhibiting growth and development of cancer cells, the method comprising delivering to an area comprising cancer cells a pimarane diterpenoid having the following structure:

US Pat. No. 10,653,637

PREVENTIVES OR REMEDIES FOR HEPATOPATHY

Kenji Kangawa, Osaka (JP...

1. A method for promoting hepatic regeneration and/or hepatic function recovery after hepatectomy, the method comprising administering to a mammal in need thereof a polypeptide derivative capable of binding to growth hormone secretagogue receptor and elevating intracellular calcium ion concentration, or a salt thereof, the derivative consisting of an amino acid sequence selected from SEQ ID NOS: 1 to 16, 19 to 22, or combinations thereof,wherein the second or third amino acid residue from the amino-terminus of the amino acid sequence comprises a serine or a group represented by the formula (2),
wherein R3 is -T2-P2-Q2, T2 is methylene, P2 is —CO—O, and Q2 is an optionally substituted C1-20 alkyl group.

US Pat. No. 10,653,631

OPTIMAL COLON TARGETING TECHNOLOGY

1. A formulation for the controlled release of one or more substances in the large intestine of a mammal, utilizingthe change of the pH value within the digestive tract for said controlled release, having an operating range, said operation range being the range of pH values, within which the pH value maximally achieved in the small intestine of said mammal may lie, in order for said controlled release to take place reliably,characterized in thatthe release is not already triggered if the lower margin of the operating range is exceededand thatif said controlled release is triggered by a decrease of the pH value within the digestive tract, the amount of said decrease maximally necessary for triggering the release is smaller than the width of the operating range,and thatit comprises
one
or
several effectively parallel arranged layer sequences, which envelop the one or more active ingredients or one or more cores comprising said one or more active ingredients,
wherein
each layer sequence comprises
a first layer which is referred to as an inner layer throughout the specification,
which
is substantially or completely soluble or permeable in aqueous solutions
only with said solutions having a pH value above a defined pH value, which is referred to as the last pH threshold value of said first layer and also constitutes the defined upper pH threshold value of said first layer, and which lies between pH 2 and pH 9,
and wherein
at least one layer sequence comprises
one or more further layers,
said one or more further layers being enveloped by or arranged below said first layer and, if applicable, sequentially enveloping each other or being sequentially arranged above each other,
and with each of said further layers being substantially or completely soluble or permeable
in aqueous solutions
having a pH value below an individual defined pH value, which is referred to as the defined lower pH threshold value of said further layer and which is lower than the defined upper pH threshold value of the layer enveloping or being arranged above said further layer,
and with each of said further layers also being substantially or completely soluble or permeable
in aqueous solutions
having a pH value above another individual defined pH value, which is referred to as the defined upper pH threshold value of said further layer and which is higher than the defined lower pH threshold value of said further layer and which is higher than the defined upper pH threshold value of the layer enveloping or being arranged above said further layer,
but with each of said further layers not being substantially or completely soluble or permeable
in aqueous solutions
having a pH value between the defined lower pH threshold value of said further layer and the defined upper pH threshold value of said further layer
and/or at least one layer sequence comprises
a most inner layer,
said most inner layer being enveloped by or arranged below said first layer and, if applicable, said one or more further layers,
with said most inner layer
being substantially or completely soluble or permeable
in aqueous solutions
only with said solutions having a pH value below a defined pH value, which is referred to as the defined first pH threshold value of said most inner layer throughout the specification and also constitutes the defined lower pH threshold value of said most inner layer and which lies between pH 2 and pH 9 and which is lower than the defined upper pH threshold value of the layer enveloping or being arranged above said most inner layer,wherein the formulation comprises at least two of said layer sequences or the formulation comprises at least one of said layer sequences comprising at least one of said further layers.

US Pat. No. 10,653,627

METHOD FOR VACUUM-ASSISTED PRESERVATION OF BIOLOGICS INCLUDING VACCINES

BOEHRINGER INGELHEIM ANIM...

1. A process for vitrifying biological material comprising the steps of:(a) formulating a liquid biological preparation, wherein the liquid biological preparation comprises at least one active biologic ingredient comprising a live bacterium and at least one stabilizer, wherein the at least one stabilizer comprises: 1) a bulking agent consisting of dextran, present in an amount of about 6% to about 10% w/v of the stabilizer; 2) one of the following combinations of sugars: glucose+raffinose; glucose+fructose; glucose+galactose; or glucose_+sucrose, wherein the glucose is present in an amount of about 1% to about 5% w/v of the stabilizer, and 3) optionally aspartic acid;
wherein the stabilizer is capable of reducing or eliminating cryogenic damage to the biologic ingredient;
(b) adding a portion of the liquid biological preparation of step (a) to at least one vial;
(c) loading the at least one vial into a temperature-controlled container, wherein the temperature of the temperature-controlled container is between ?15° C. and 10° C.; and
(d) reducing the moisture content of the biological preparation to less than about 5% by weight by controlled changes in pressure and temperature, comprising the following steps in the following order:
1) reduction in pressure from about 10-30 mbar to about 5 mbar, over about 5-15 minutes, then holding the pressure at about 5 mbar for about 40-50 minutes;
2) reduction in pressure from about 5 mbar to about 3 mbar, over about 5-10 minutes, then holding the pressure at about 3 mbar for about 10-40 minutes;
3) reduction in pressure from about 3 mbar to about 1.5-2 mbar, over about 5-10minutes, then holding the pressure at about 1.5-2 mbar for about 5-160 minutes; thereby reducing the moisture content of the biological preparation to less than about 5% by weight, and thereby vitrifying the biological material, and
wherein the one or more biologic ingredients remains at least 85% viable for at least a year after vitrification, thereby the one or more biologic ingredients is stabilized.

US Pat. No. 10,653,626

POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGINE

Shanghai Aucta Pharmaceut...

1. A powder formulation suitable for reconstitution with a pharmaceutically acceptable carrier to form a stable suspension oral dosage form comprising a powdered mixture oflamotrigine or a pharmaceutically acceptable salt thereof in powder form; and
xanthan gum in powder form in an amount ranging from about 2% to about 4% w/w of the powder formulation, further wherein upon reconstituting the powder formulation into an aqueous suspension, said suspension provides a sedimentation volume ratio of more than 0.8 for at least 10 hour.

US Pat. No. 10,653,623

HYDROCORTISONE ACETATE SUPPOSITORY FORMULATION FOR TREATMENT OF DISEASE

Cristcot LLC, Concord, M...

1. A suppository having a weight of about 2 g and comprising about 90 mg hydrocortisone acetate, about 5 mg to about 20 mg colloidal silicon dioxide and an oleaginous base that includes triglycerides, wherein the suppository releases at least about 80% of the hydrocortisone acetate at about 180 minutes following exposure to dissolution media comprising a buffered 5% w/v sodium lauryl sulfate solution having a final pH in the range of about 6.8-7.0.

US Pat. No. 10,653,622

INDIVIDUALIZED SOLID DOSAGE PRODUCTS AND A SYSTEM AND METHOD FOR THE GLOBALLY INTEGRATED PHARMACEUTICAL MANUFACTURING AND ITS MONITORING THEREOF

Pharmacoustics Technologi...

1. A method for monitoring and calibrating each of a plurality of parallel production units in a global network of production units, each respective production unit manufacturing at least one solid dosage product, the method comprising:a) manufacturing a calibration model block, the calibration model block being used to establish requirements for an acceptable final dosage form, wherein the acceptable final dosage form includes a first plurality of compartments, wherein at least two compartments of the first plurality of compartments have different dissolution properties;
b) at each respective production unit within the global network:
i) manufacturing a digestible carrier block, the digestible carrier block defining a second plurality of compartments which correspond to the first plurality of compartments, each respective compartment within the second plurality of compartments is configured to receive an active pharmaceutical ingredient;
ii) filling a respective compartment within the second plurality of compartments with a respective active pharmaceutical ingredient;
iii) coating the digestible carrier block with one or more coating layers to form the at least one solid dosage product;
iv) online real-time monitoring using Process Analytical Technology systems of:
a printing head responsible for manufacture of the digestible carrier block, wherein the monitoring includes comparing the dissolution properties of the digestible carrier block with the dissolution properties of the calibration model block,
a first filler head responsible for filling of each respective compartment,
the active pharmaceutical ingredient,
a second filler head responsible for each coating layer, and
each of the one or more coating layers; and
v) transmitting via a wired or wireless network to a central computing location results from the online real-time monitoring to establish online monitoring reports;
c) providing computer-executable instructions at the central computing location for comparing the online monitoring reports from each respective production unit with the established requirements of the acceptable final dosage form to identify non-complying production units; and
d) if needed, modifying each of the non-complying production units to thereby manufacture the at least one solid dosage product satisfying the established requirements for the acceptable final dosage form based in part on the calibration model block.

US Pat. No. 10,653,621

BIODEGRADABLE DRUG DELIVERY SYSTEMS FOR THE SUSTAINED RELEASE OF PROTEINS

Allergan, Inc., Irvine, ...

1. A method for making a biodegradable intraocular implant that provides continuous release of a protein in a biologically active form for at least 90 days after placement of the implant in an eye of a mammal, the method comprising:a. providing a dry powder comprising one or more proteins and, optionally, one or more excipients, salts, buffering agents, preservatives, polyelectrolytes, or combination thereof;
b. blending the dry powder with at least two poly(D,L-lactide-co-glycolide) copolymers to form a mixture wherein one of the copolymers has an ester end group and the other copolymer has an acid end group;
c. extruding the mixture at a temperature between 60° C. and 90° C. to form a filament;
d. cutting the filament to form an implant 0.5 to 10 mm in length suitable for placement in an ocular region of an eye.

US Pat. No. 10,653,602

FOAM BOOSTING SACCHARIDE BLEND

Coast Southwest Inc., Pl...

1. A foamable liquid cleansing composition comprising:a foam booster comprising a saccharide blend having:
(a) 30 wt. % to 50 wt. % of an aldohexose or mixture of aldohexoses;
(b) 20 wt. % to 55 wt. % of a ketohexose or mixture of ketohexoses; and
(c) 10 wt. % to 25 wt. % of a disaccharide or mixture of disaccharides; and
a foaming detergent or surfactant,
wherein the composition is configured to foam and cleanse skin and/or hair.

US Pat. No. 10,653,600

COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR COMPOUND CAPABLE OF ESTABLISHING HYDROGEN BONDS, AND TWO PARTICULAR DISTINCT SILICONE OILS

1. A solid lipstick composition comprising, in a cosmetically acceptable medium:(a) a supramolecular compound in an amount of 40 to 20% by weight of active material, relative to the total weight of the composition having the formula:

(b) two distinct non-volatile silicone oils in a total content ranging from 40% to 65% by weight relative to the total weight of the composition, wherein a first non-volatile silicone oil is phenyl trimethicone and a second non-volatile silicone oil is trimethylsiloxyphenyl dimethicone
the first non-volatile silicone oil is present in a content greater than or equal to the second non-volatile silicone oil; and
(c) polyethylene wax in a content of less than or equal to 20% by weight relative to the total weight of the composition,
wherein the solid lipstick composition does not comprise a film former and
wherein the solid lipstick composition does not break during application and which is stable at 23° C. and at 45° C. for 1 month defined by no observable exudation or phase separation.

US Pat. No. 10,653,592

MICROCAPSULES AND COMPOSITIONS PROVIDING CONTROLLED RELEASE OF ACTIVES

Noxell Corporation, Hunt...

1. A microcapsule comprising an emulsion droplet encapsulated by a metallic film, wherein the emulsion droplet comprises an emulsifier disposed around a liquid core material, wherein the emulsion droplet comprises particles of a first metal selected from palladium, platinum, silver, gold, copper, nickel, tin, and a combination thereof, a second metal selected from silver, gold, nickel, copper, and a combination thereof, the metallic film is formed on said emulsion droplet, and whereinthe liquid core material comprises a volatile material, and the particles of the first metal are nanoparticles,
the density of said particles of the first metal on the emulsion droplet is from 0.0001 g/m2 to 0.01 g/m2 of the surface area of the emulsion droplet
the metallic film has:
(i) a maximum thickness of 1000 nm; and
(ii) a minimum thickness of 1 nm;
the emulsifier further comprises a stabilizer stabilizing the nanoparticles; and
the nanoparticles of the first metal are charge-stabilized nanoparticles.

US Pat. No. 10,653,588

COMPOSITION FOR PROTECTING THE KERATIN MATERIALS FROM SUN

1. A composition, comprising:a) at least one UV filter;
b) spherical composite particles comprising:
i) spherical particles A1 having a mean size of greater than 0.1 microns and less than 1 micron, the surface of said particles A1 being at least partially covered with titanium dioxide particles and the core of the particles comprising styrene/methyl methacrylate copolymer; and
ii) spherical particles A2 having a mean size of greater than or equal to 2 microns, the surface of said particles A2 being covered with at least titanium dioxide particles and the core of the particles comprising poly(methyl methacrylate); and
c) at least one anti-oxidation active ingredient selected from the group consisting of
I) a compound according to formula (I)

wherein
each X independently represents —OPO3Y, wherein Y is hydrogen, Li, Na, or K;
II) a dimer peptide according to formula (II):

III) a tocopherol or a derivative thereof; and
IV) a mixture thereof.

US Pat. No. 10,653,587

ARRAY OF ABSORBENT ARTICLES INCLUDING A FRAGRANCE ACCORD AND A LOTION COMPOSITION

1. An array of at least two commonly-branded wipes products comprising a first wipes product and a second wipes product, wherein:the first wipes product comprises:
a first supply of wipes formed from a first substrate, the first supply of wipes being moistened with a first functional lotion composition, the first functional lotion composition comprising:
a first fragrance accord; and
a first lotion formula;
the second wipes product comprises:
a second supply of wipes formed from a second substrate, the second supply of wipes being moistened with a second functional lotion composition, the second functional lotion composition comprising:
a second fragrance accord; and
a second lotion formula;
wherein the second fragrance accord is different from the first fragrance accord, and wherein the second lotion formula is different from the first lotion formula;
wherein the first lotion formulation has a first peak viscosity and the second lotion formula has a second peak viscosity, and wherein the first peak viscosity is less than the second peak viscosity;
wherein the first functional lotion composition has a peak viscosity from about 5 mPa·s to about 65 mPa·s;
wherein the second functional lotion composition has a peak viscosity greater than about 75 mPa·s; and
wherein the first functional lotion composition comprises less than 0.3 wt. % sodium benzoate.

US Pat. No. 10,653,585

PALLADIUM BASED ALLOYS

Ivoclar Vivadent, Inc., ...

1. A dental article comprising;a dental alloy substrate free of gold, copper, silver and cobalt comprising palladium, platinum, gallium, molybdenum, chromium, ruthenium and rhenium and having a CTE in the range of about 11.5 to about 13.0×10?6/° C. at 25-500° C.; and
a ceramic or glass ceramic having a CTE in the range of about 8.0 to about 13×10?6/° C. at 25-500° C. pressed onto the dental alloy substrate.

US Pat. No. 10,653,584

TABLET AND CAPSULE DISPENSING ASSEMBLY

Pill Development Group, L...

1. A tablet and capsule dispensing assembly, comprising:a case having a superior component and an inferior component, the superior component and the inferior component operatively arranged to form a first cavity therebetween, the superior component comprising an inner circumferential surface including a first plurality of teeth;
a tablet disc arranged within the first cavity, the tablet disc having a plurality of tablets disposed about a circumference of the tablet disc, and arranged to rotate within the case; and,
a lock arranged to prevent rotation of the tablet disc in a first rotational direction during a first predetermined time interval, the lock comprising:
a first component, the first component comprising:
a display and a first circuit electrically connected to the display; and,
a second component, the second component comprising:
an actuator;
a pivotable catch arranged to engage with the first plurality of teeth to prevent rotational movement of the lock in the first rotational direction with respect to the case;
a second plurality of teeth disposed on an outer circumferential surface of the second component; and,
a ratchet operatively arranged to engage with the second plurality of teeth and the case.

US Pat. No. 10,653,583

PROGRAMMABLE PILL BOX ASSEMBLY

1. A programmable pill box assembly being configured to emit an audible reminder for taking medication, said assembly comprising:a pill box having a plurality of compartments therein wherein each of said compartments is configured to have pills positioned therein, said plurality of compartments including a first bank of compartments and a second bank of compartments;
a plurality of doors, each of said doors being hingedly coupled to said pill box, each of said doors being aligned with a respective one of said first and second banks of compartments for opening and closing said respective first and second banks of compartments, each of said doors having a tab extending downwardly therefrom;
a sensing unit being coupled to said pill box, said sensing unit being in operational communication with each of said doors such that said sensing unit senses when each of said doors is opened or closed, said sensing unit comprising
a pill box control circuit being coupled to said pill box, said pill box control circuit receiving an open input and a closed input, said pill box control circuit including an electronic memory, said electronic memory storing a database comprising a unique identity assigned to each of said compartments in said pill box, said database further comprising a predetermined schedule for taking the pills in each of said compartments,
a plurality of sensors, each of said sensors being coupled to said pill box, each of said sensors being positioned in a respective one of said compartments, each of said sensors being electrically coupled to said pill box control circuit, said unique identity assigned to each of said compartments having a respective one of said sensors being associated therewith, wherein each of said sensors emits a detection signal, said tab on said door being aligned with said respective compartment being aligned with said sensor in said respective compartment when said door on said respective compartment is closed, said detection signal emitted by said sensor in said compartment detecting said tab on said respective door when said respective door is closed thereby communicating said closed input to said pill box control circuit, said pill box control circuit receiving said open input when said detection signal emitted from any of said sensors does not detect said tab on said respective door;
a transmission unit being removably coupled to said pill box, said transmission unit being in electrical communication with said sensing unit when said transmission unit is removably coupled to said pill box, said transmission unit transmitting an alert signal when said sensing unit senses that a respective one of said doors has not been opened at a predetermined time;
a bracelet being worn on a wrist of the user, said bracelet being in remote communication with said transmission unit, said bracelet vibrating when said transmission unit broadcasts said alert signal wherein said bracelet is configured to alert the user to take the pills in one of said compartments in said pill box; and
a personal electronic device being carried by the user, said personal electronic device being in remote communication with said transmission unit, said personal electronic device alerting the user when said transmission unit transmits said alert signal.

US Pat. No. 10,653,582

TOE CORRECTOR

1. A toe corrector comprising:a bottom part;
correction protrusions configured to protrude between adjacent toes from an upper surface of the bottom part to correct the toes;
a connection part configured to connect upper ends of the correction protrusions so that correction protrusions are fitted on toes to be fixed; and
light emitting units configured to emit light by self-generating electricity, which are provided inside the bottom part and the correction protrusions,
wherein the bottom part includes:
a pad provided inside the bottom part;
a heating line arranged zigzag on one side surface of the pad;
a power transmission portion configured to receive power from an outside so that the power transmission portion is connected to an end portion of the heating line and provided to be exposed to the outside of the bottom part and; and
an acupressure portion configured to perform acupressure on skin by a plurality of protrusions formed on the upper surface of the bottom part in contact with a part of the skin between a sole and toes,
wherein the correction protrusions include:
a first protrusion configured to protrude between a big toe and a long toe;
a second protrusion configured to protrude between the long toe and a third toe;
a third protrusion configured to protrude between the third toe and a fourth toe; and
a fourth protrusion configured to protrude between the fourth toe and a little toe,
wherein upper edges of the first, second, third, and fourth protrusion are formed in chamfer shapes and edges formed in the chamfer shapes are formed round, sides of the first, second, third, and fourth protrusion in contact with sides of the toes are formed to be recessed toward an inside of the first, second, third, and fourth protrusion to cover the sides of the toes,
wherein the connection part includes:
a first connecting bridge configured to connect the upper ends of the second protrusion and the third protrusion; and
a second connecting bridge configured to connect the upper ends of the third protrusion and the fourth protrusion,
wherein one end of the first connecting bridge is connected to the second protrusion and the other end is connected to the third protrusion while a first coupling protrusion inserted and coupled to a first recessed groove formed in an upper surface of the third protrusion is formed at the other end, and
wherein one end of the second connecting bridge is connected to the third protrusion and the other end is connected to the fourth protrusion while a second coupling protrusion inserted and coupled to a second recessed groove formed in an upper surface of the fourth protrusion is formed at the other end,
wherein a light emitting unit of the light emitting units includes:
a piezoelectric element provided inside the bottom part and the correction protrusions and configured to self-generate electricity when an external force is applied thereto;
a thin film battery which stores power generated from the piezoelectric element; and
a light emitting diode (LED) provided on an upper surface of the correction protrusions, configured to receive the power stored in the thin film battery, and configured to emit light, and
wherein the toe corrector further includes:
a logo part bonded on an upper surface of at least one of the correction protrusions and a logo is printed on an upper surface of the logo part; and
a fragrance emitting layer formed on the upper surface of the correction protrusions by applying a mixture in which a fragrance is added to a mixed UV coating agent, the mixed UV coating agent comprising:
an ultraviolet curable oligomer which influences physical properties to form a coating film for a surface on the upper surface of the correction protrusions,
an ultraviolet curable monomer which is a diluent reacting with the oligomer,
a photoinitiator which induces polymerization of the oligomer and the monomer, and
an additive which is chemically combined with a coating film formed by the oligomer and the monomer to improve durability or slipperiness of the surface on the upper surface of the correction protrusions.

US Pat. No. 10,653,581

PERSONAL USE EXTRACORPOREAL LOW FREQUENCY SHOCK WAVE INSTRUMENT AND METHODS OF USING SAME

1. A treatment device comprising:a housing having a longitudinal axis extending between a proximal end and a distal end;
a motor disposed within the housing;
a drive shaft operatively coupled to the motor;
a compression spring at least partially disposed about the drive shaft;
a helical cam disposed adjacent the compression spring, the helical cam having a first flat end facing the proximal end of the housing, and a second end facing the distal end of the housing and having at least one discontinuity, wherein the drive shaft passes through the first and second ends of the helical cam and includes at least one cam follower configured to travel along the second end of the helical cam;
a hammer coupled to one of the helical cam and the drive shaft and moveable therewith; and
a tip disposed adjacent the distal end;
wherein the hammer is configured and arranged to strike the tip at repeated intervals, and wherein each strike of the tip by the hammer results in a shock wave that has a frequency of approximately 10 to 20 hertz.

US Pat. No. 10,653,580

BEAUTY DEVICE

MTG CO., LTD., Nagoya-sh...

1. A beauty device comprising:a handle formed with a housing portion in a recessed shape;
an inner lid mounted to the handle to seal the housing portion;
a pair of support shafts extended from an end portion at one side of the handle;
a pair of rotation bodies rotatably supported around the support shafts;
a water stop portion intervened between the housing portion and the inner lid;
an outer lid which closes an opening of the housing portion while covering the inner lid,
wherein the water stop portion contacts with a peripheral edge of the opening of the housing portion in a fluid-tight manner, and
the outer lid is fitted in the housing portion in a state where an outer circumference surface of the outer lid is arranged to face an inner circumference surface of the opening of the housing portion and a part where the outer circumference surface and the inner circumference surface face each other is visible from an outside, the inner circumference surface being formed to extend in a depth direction of the housing portion; and
a beauty effect applying portion arranged at another end portion of the handle, wherein the beauty effect applying portion comprises a spherical portion that is configured to apply a beauty effect to skin by contacting the skin, and the spherical portion is connected to a fixed shaft, and
the fixed shaft is received within the handle from the another end portion of the handle and the inner lid is configured to engage with the pair of support shafts, and the inner lid is configured to place a shaft holder in a position to engage and lock the fixed shaft to the handle.

US Pat. No. 10,653,579

MOTORIZED LIFE CANE

1. A motorized lift cane used to aid a mobile person to rise from a sitting position to a standing position and to lower said person from the standing position to the sitting position, said motorized lift cane comprising:a) a cylindrical hollow upper shaft means and a cylindrical hollow lower shaft means, a diameter of said cylindrical hollow lower shaft means being smaller than a diameter of said cylindrical hollow upper shaft means and being partially slidably contained therein,
b) said upper shaft means including a handle on an upper shaft end, a switch means secured to said upper shaft means along a top closer to the handle, a rechargeable battery means secured within the said upper shaft or externally to the said upper shaft, a low battery light indicator means, a fully charged battery light indicator means, a battery charger connector means, and a battery powered linear actuator means connecting said upper shaft means and said lower shaft means,
c) an electrical conductor means extending between said battery means, said switch means, said low battery light indicator means, said fully charged battery light indicator means, said battery charger connector means, and said linear actuator means for operation of said linear actuator means,
d) said lower shaft means including an attached tip,
e) said linear actuator means comprises a tubular upper cover section and a tubular lower cover section, said tubular upper cover section attached to said cylindrical hollow upper shaft means and said tubular lower cover section attached to said cylindrical hollow lower shaft means.

US Pat. No. 10,653,578

GUS CUSHION ANKLE HOLDER FOR AN INVERSION TABLE

1. A cushioned ankle holder for an inversion table comprising:at least one gas-filled bladder that is connected to a flexible backing;
said flexible backing being configured to contour to a structural support frame;
a cosmetic skin that covers said at least one gas-filled bladder;
said cosmetic skin has a cord or string that is captured within a peripheral sleeve of said cosmetic skin;
said cord or string is a draw string that is configured to gather said cosmetic skin around said at least one gas-filled bladder and said structural support frame, wherein said structural support frame includes at least one slot that captures said cord or string, wherein the cord or string is held within the slot by friction;
said structural support frame is connected to an opening and closing ratcheting mechanism whereby said opening and closing mechanism is configured to retain an ankle of a person, and
said opening and closing mechanism is secured to an inversion table.

US Pat. No. 10,653,577

RELOCATION MODULES AND METHODS FOR SURGICAL FIELD

1. A module for housing electronic and electromechanical equipment during surgery, the module comprising:a housing having a lower section and a tower-like upper section,
wherein the lower section is configured to house unrelated waste heat-producing electronic and electromechanical surgical equipment during surgery,
wherein a rear portion of the lower section is configured to fit into an unused space under an arm-board of a surgical table,
wherein the tower-like upper section is located above the lower section, wherein the tower-like upper section is configured to be positioned adjacent an anesthesia side of an arm-board of the surgical table, and
wherein the upper section is configured to accommodate mounting of equipment controls, display screens and monitor screens at a convenient height for viewing and operating; and
at least a portion of an anesthetic gas machine is disposed in the housing.

US Pat. No. 10,653,576

APPARATUS FOR ASSISTING TOILET USER IN STANDING UP

1. An apparatus for aiding a user of a toilet in standing up, comprising:a movable seat movably mounted to the toilet; and
a seat actuator arranged adjacent to the toilet and actuating the movable seat to move having at least one of lifting movement and pivoting movement,
wherein the seat actuator comprises:
a base frame adjacent to and stationarily mounted to the toilet;
a driver mounted to the base frame;
a driving frame driven to reciprocate by the driver; and
a link assembly comprising a first side connected to the driving frame and a second side connected to a connection link coupled to the movable seat and producing lifting movement and pivoting movement of the movable seat in accordance with reciprocation of the driving frame,
wherein the link assembly comprises:
a vertical movement link comprising a first side connected to and moving along a main operating route guide hole and a second side pivotably connected to the connection link and produces the lifting movement of the movable seat in accordance with the reciprocation of the driving frame; and
a pivoting movement link comprising a first side pivotably connected to the driving frame and a second side pivotably connected to the connection link and produces the pivoting movement of the movable seat in accordance with the reciprocation of the driving frame,
wherein the driving frame comprises:
the main operating route guide hole; and
a sub operating route guide hole having the same shape as the main operating route guide hole and spaced apart from the main operating route guide hole equidistantly at every point,
wherein the base frame comprises a vertical guide hole,
wherein the first side of the vertical movement link is penetrated by a main guide pin, the main guide pin is inserted in the main operating route guide hole while penetrating the first side of the vertical movement link, and a sub guide pin is inserted in the sub operating route guide hole, and
wherein a connection guider is inserted in the vertical guide hole to be slidable in a vertical direction and connects the main guide pin and the sub guide pin in a vertical direction.

US Pat. No. 10,653,575

PATIENT SUPPORT APPARATUS AND METHODS

11. A control unit for a mattress having two or more inflatable zones, the control unit comprising:two or more primary fluid sources each having a first capacity and configured to be coupled to a different one of the two or more zones of the mattress;
a secondary fluid source having a second capacity that is greater than the first capacity of each primary fluid source, the secondary fluid source configured to be coupled to each of the two or more zones of the mattress;
a controller coupled to the two or more primary fluid sources and to the secondary fluid source;
where the controller is configured such that if the primary fluid sources and the secondary fluid source are coupled to the two or more zones of a mattress, the controller will activate the secondary fluid source after the two or more zones have been initially inflated past a lower threshold pressure to provide fluid to the two or more zones if the pressure in at least one of the two or more zones is below the lower threshold pressure.

US Pat. No. 10,653,574

MEDICAL WALKER DOCKING STATION (IMWDS)

1. An improved medical walker docking station stabilizing main platform base device for automatically stabilizing a medical walker to aid the user of the medical walker to rise from a sitting position from an object upon which the user of the medical walker is sitting or at any other time when the user of the medical walker attempts to access the medical walker, where by the weight of the medical walker user standing on the medical walker stabilizing platform base device stabilizes the medical walker stabilizing platform base device which in turn stabilizes the medical walker via an automatic movement restrictor assembly coupled to the medical walker stabilizing main platform base device comprising:a stand-alone main platform base disposed on a surface and covering an area encompassing multiple legs of the medical walker, such that the medical walker includes two front legs with wheels attached to a lower portion of each front leg via a front axle, stand-alone main platform base being placed adjacent to the object upon which the use of the medical walker is sitting or even adjacent to where the user of the medical walker is standing,
an automatic movement restrictor assembly coupled to the main platform base, the automatic movement restrictor assembly when fully automatically engaged disposed perpendicular to the upper surface of the main platform base for engaging with a portion of the medical walker's front axle, said automatic movement restrictor assembly having an engaged position and a disengaged position and can be recessed into the main platform base wherein the engaged position, the automatic movement restrictor assembly's capture plate engages with the medical walker's front axle between the medical walker's front wheel and each medical walker's corresponding front leg such that the automatic movement restrictor assembly restricts movements of the medical walker in a direction perpendicular to the upper surface of the main platform base, but allows movement of the medical walker in a direction parallel with the upper surface of the main platform base which is also parallel to the lower surface of the main platform base and, wherein in the disengaged position the automatic movement restrictor assembly is no longer disposed perpendicular to the upper surface of the main platform base but lies parallel to and flat on or flush with the upper surface of the main platform base,
wherein a non-capture/non cut-out portion of said automatic movement restrictor assembly hangs over the side of the main platform base ready to be activated to be disposed perpendicular to the plane of the horizontal surface of the main platform base as each of the two medical walker's front wheels move backwards and depress downwards on the non-capture/non cut-out portion of said automatic restrictor assembly placing the entire automatic movement restrictor assembly in the proper vertical position to capture the medical walker's front axles and thus stabilize the medical walker; and
wherein the automatic movement restrictor assembly is attached to the main platform base via a hinge.

US Pat. No. 10,653,573

FITTING SYSTEM AND METHOD FOR MODULAR PRESSURE RELIEF CUSHION

CASE WESTERN RESERVE UNIV...

1. A method of manufacturing a customized cushion that reduces risk of formation of pressure ulcers in a user, the method comprising:a) creating a pressure map based upon the user;
b) associating portions of the pressure map with a modular array of regularly spaced gel balls arranged within a uniform array;
c) determining individual loading of each ball based upon location of each ball relative to the pressure map and concurrently determining the average pressure on a group of adjacent balls based upon the location of the group of adjacent balls relative to the pressure map; and
d) adjusting viscosity of each ball within the array based upon the determinations in step (c) and providing it to a foam substrate.

US Pat. No. 10,653,572

GOWN SYSTEM

1. A gown dispenser system, comprising:a plurality of gowns, each gown, unfolded, having an upper portion having a front region and the back region, a left and a right sleeve, each having an arm opening into the upper portion, of a length to cover an arm of a person, and an upper head opening, and a front apron portion having a width from the left to the right sleeve, extending downward from the upper portion for a height to cover a major portion of a person's body, each gown including a radio-frequency identification (RFID) tag, the gowns being folded and stacked with the back region facing up, such that, grasping and pulling on the back region of a gown on top of the stack removes that gown from the stack and exposes the back region of the next gown in the stack; and
an enclosure containing the stack of gowns with the back regions facing up, the enclosure having an opening in one surface exposing the back region of the gown at the top of the stack, enabling a user to grasp the exposed back region, and to pull the topmost gown from the enclosure, exposing the next gown in the stack,
wherein the gowns are drawn from the enclosure one-at-a-time, at need.

US Pat. No. 10,653,571

ARTICLE COMPRISING ODOR CONTROL COMPOSITION

1. A disposable absorbent article comprising a longitudinal centerline and a lateral centerline, a front waist region with a front waist edge, a rear waist region with a rear waist edge, a crotch region disposed between the front and rear waist regions, and two spaced apart longitudinal side edges joining the front waist edge to the rear waist edge, comprising:a) a topsheet;
b) a backsheet;
c) an absorbent core disposed between the topsheet and the backsheet, the absorbent core comprising a core wrap; and
d) a liquid management system disposed between the topsheet and the absorbent core, the liquid management system comprising a distribution layer, wherein the distribution layer comprises a distribution layer surface area that faces the core wrap;
wherein an odor control composition is directly joined to a core wrap surface area facing the liquid management system;
wherein the core wrap surface area facing the liquid management system comprises a continuous surface free of apertures;
wherein the distribution layer surface area is less than the core wrap surface area; and
wherein the odor control composition is disposed only on a portion of the core wrap surface area that is overlapped by the distribution layer.

US Pat. No. 10,653,570

ABSORBENT ARTICLES WITH IMPROVED CORE

1. An absorbent article comprising a topsheet, a backsheet and an absorbent core disposed between the topsheet and the backsheet, wherein the absorbent core comprises:a first absorbent layer comprising a first substrate and a mixed layer deposited on the first substrate, the mixed layer comprising a mixture of first superabsorbent polymer particles and cellulosic fibers; and
a second absorbent layer comprising a second substrate, a layer of second superabsorbent polymer particles deposited on the second substrate, wherein the layer of second superabsorbent polymer particles is substantially cellulose free;
wherein the first absorbent layer and the second absorbent layer are combined such that the mixed layer and the layer of second superabsorbent polymer particles are disposed between the first and second substrates, and wherein the first absorbent layer is placed closer to the topsheet than the second absorbent layer;
wherein the second absorbent layer comprises one or more permanent channels, the channels being free of the second superabsorbent polymer particles;
wherein the first absorbent layer comprises one or more permanent channels;
wherein the one or more channels in the first absorbent layer and the second absorbent layer are at least partially overlapping and the first and second substrates are bonded to each other through the one or more channels; and
wherein the first substrate is C-wrapped along longitudinal edges of the core to form C-flaps and the second substrate is disposed inwardly of the C-flaps.

US Pat. No. 10,653,569

ABSORBENT ARTICLE

1. An absorbent article having a longitudinal direction and a transverse direction, the absorbent article comprising:a front portion;
a rear portion;
a center portion located between and bordering to the front and rear portions, wherein a maximal length of the front portion in the longitudinal direction is 15% of a maximal length the absorbent article in the longitudinal direction, and a maximal length of the rear portion in the longitudinal direction is 20% of the maximal length the absorbent article in the longitudinal direction;
an elongated middle section extending in the longitudinal direction of the absorbent article and centered around a longitudinal center line, and
two elongated side sections extending in the longitudinal direction of the absorbent article, wherein one side section is located on each side of the middle section and extends in transverse direction from a lateral edge of the middle section to a lateral edge of the absorbent article, wherein a length of the middle section in the transverse direction is in the range of 10-60% of the maximal length of the absorbent article in the transverse direction;
a liquid pervious topsheet bonded to an underlying layer by a plurality of large and small binding points, wherein the small binding points have a surface area in the range of 0.01-2.5 square millimeters, and wherein the large binding points have a surface area above 2.5 square millimeters; and
a discontinuous printed layer forming a color printing pattern on a surface of the topsheet or the underlying layer, wherein the color printing pattern is visible on a topsheet side of the absorbent article,
wherein all printed surface area of the color printing pattern, onto which a disc with a diameter of 1.5 millimeters can be mapped without extending beyond a periphery of the printed surface area, defines one or more continuous colored regions, and each continuous colored region within at least the center portion of the absorbent article is substantially free from large binding points,
wherein at least 75% of the one or more continuous colored regions within the center portion of the absorbent article is located in any of the side sections,
wherein at least 30% of the surface area of the one or more discontinuous colored regions within the center portion of the absorbent article is located in the middle section,
wherein at least 30% of the binding points located within the one or more discontinuous colored regions are large binding points,
wherein the total surface area of the one or more continuous colored regions amount to 3-40% of the total surface area of the center portion of the topsheet, and
wherein the total surface area of the one or more discontinuous colored regions amount to 20-80% of the total surface area of the center portion of the topsheet.

US Pat. No. 10,653,568

DISPOSABLE PULL-ON DIAPER

Unicharm Corporation, Eh...

1. A disposable pull-on diaper having a lateral direction and a longitudinal direction-comprising:a lower torso cover that assumes a tubular shape and defines at least a front waist region and a back waist region among the front waist region, the back waist region and a crotch region;
an absorbent chassis that comprises absorbent structure, extends between the front waist region and the back waist region, and has a front end portion and a back end portion adapted to overlap the front waist region and the back waist region, respectively;
a waist opening; and
a pair of leg-openings, wherein,
the lower torso cover has an elastic region in which a plurality of elastic elements extend in the lateral direction and contractibly secured thereto under tension,
the absorbent chassis comprises by an absorbent body included in the absorbent structure, a liquid-permeable bodyside liner and a liquid-impermeable backsheet and includes a cover sheet to wrap the absorbent body wherein the cover sheet extends outward in the longitudinal direction beyond the absorbent body,
the front end portion of the absorbent chassis has:
a front end portion joined to the lower torso cover in the elastic region; and
a front end adjoining portion extending adjacent to the front end portion on the side of the crotch region,
an area extending adjacent to the front end adjoining portion on the side of the crotch region is joined to an inelastic region extending adjacent to the front end adjoining portion on the side of the crotch region and including none of elastic elements extending in the lateral direction,
the absorbent body extends at least from the crotch region to the front end adjoining portion and the front end portion is defined by the portion of the cover sheet extending outward beyond the absorbent body,
the front end adjoining portion in the front end portion has two laterals that overlap with the elastic region and are opposite to each other in the lateral direction and each of the two laterals is partially but not completely joined to the elastic region, and
an area extending in the lateral direction between the two laterals overlaps with the elastic region and is not joined to the elastic region.

US Pat. No. 10,653,567

INCONTINENCE DETECTION PAD VALIDATION APPARATUS AND METHOD

Hill-Rom Services, Inc., ...

1. An incontinence pad comprising:an absorbent material;
an electrical sheet adjacent the absorbent material;
the electrical sheet comprising:
a layer of material shaped generally as a rectangle having first and second long sides and first and second short sides,
an RFID tag coupled to the layer closer to the first short side than the second short side, and
first and second electrodes on the layer and electrically coupled to the RFID tag, the first and second electrodes including first, second, third and fourth electrode segments that are generally parallel with the first and second long sides of the layer, the second and third electrode segments being situated between the first and fourth electrode segments, the second and third electrode segments being spaced apart by a first distance that is at least twice a second distance defined between the first and second electrode segments and between the third and fourth electrode segments;
wherein the RFID tag includes a memory location, wherein an authentication code is stored in the memory location and is configured to cause a reading system to alert based on the detection of fluid; and
wherein the RFID tag includes a transmitter configured to transmit a signal indicating the presence of fluid, wherein the transmitter is further configured to transmit the authentication code.

US Pat. No. 10,653,566

METHOD AND APPARATUS FOR CONTROLLING AND ADVANCING AN ABSORBENT ARTICLE

1. A method of transferring discrete absorbent articles from a first carrier apparatus to a second carrier apparatus, the method comprising:advancing an absorbent article with a first carrier apparatus in a machine direction, wherein the absorbent article comprising a belt including a first end region and a second end region separated by a central region, and wherein the first end region comprises a waist region fold;
transferring the absorbent article to a transfer apparatus, the transfer apparatus comprising a transfer member connected with a frame, the transfer member including a receiving surface, wherein the receiving surface defines a plurality of apertures, wherein the plurality of apertures is separated into a first group of apertures and a second group of apertures, wherein a fluid supply member is located adjacent to the transfer apparatus;
activating at least a portion of the first group of apertures by fluid being pulled through the apertures creating vacuum such that the second end region and the central region are held to the receiving surface;
rotating the frame about a first axis of rotation;
unfolding the waist region fold of the first end region as the frame rotates about the first axis of rotation;
applying a positive air pressure from the fluid supply member such that the positive air pressure engages the first end region, wherein the first end region is guided to the receiving surface;
activating the second group of apertures by fluid being pulled through the apertures creating vacuum such that the first end region is held to the receiving surface;
rotating the transfer member about a second axis of rotation as the transfer apparatus rotates about the first axis of rotation, wherein the second axis of rotation is orthogonal to the first axis of rotation; and
transferring the absorbent article from the transfer apparatus to a second carrier apparatus.

US Pat. No. 10,653,565

METHODS AND APPARATUSES FOR SEPARATING DISCRETE ARTICLES FROM CONTINUOUS WEBS

1. A cutting assembly for separating absorbent articles from continuous webs of absorbent articles, the cutting assembly comprising:a frame;
a first cutting roll rotatably positioned on the frame, wherein the first cutting roll comprises a first cutting device;
a second cutting roll rotatably positioned on the frame, wherein the second cutting roll comprises a second cutting device;
wherein the first cutting roll has a different diameter than the second cutting roll;
a drive mechanism configured to rotate the first cutting roll and/or the second cutting roll; and
a shifter, wherein the shifter is configured to move the first cutting roll between an online position and an offline position, and wherein the shifter is configured to move the second cutting roll between an offline position and an online position.

US Pat. No. 10,653,564

METHOD FOR MANUFACTURE OF ABSORBENT ARTICLE

UNICHARM CORPORATION, Eh...

1. A method for manufacturing an absorbent article having a base material, the method comprisinga first step for providing a base material having microcapsules confining a coloring agent,
a second step for breaking the microcapsules in a prescribed pattern in the base material to release the coloring agent into the base material in the prescribed pattern, and
a third step for applying a developer onto the base material in which the coloring agent has been released in the prescribed pattern, to react and the coloring agent and the developer to thereby effect coloring in at least a portion of the prescribed pattern.

US Pat. No. 10,653,563

BRA LINERS

1. A bra liner, comprising:a planar body having at least three outer straight sides and including a left portion, a right portion and a central portion between said left and right portions, said central portion including a foldable flap separated from said left and right portions,
said body comprising absorbent material; and
wherein said body has a truncated triangular shape having a left corner at a lower left region of said left portion, a right corner at a lower right region of said right portion, and a bottom peripheral edge that is common to said right, left and central portions and forms a lower outer straight side of said body between said left and right corners, an angled left part of said left portion forming a left outer straight side of said body, and an angled right part of said right portion forming a right outer straight side of said body,
said left corner of said body includes a peripheral edge that directly connects a left end of said lower outer straight side to said left outer straight side,
said right corner of said body includes a peripheral edge that directly connects a right end of said lower outer straight side to said right outer straight side, said left corner and said right corner being distanced from said central portion such that said lower outer straight side, said left outer straight side and said right outer straight side are between said left corner and said right tip region,
said left outer straight side extending at an angle upward from said left corner and inward from said left corner toward said central portion,
said right outer straight side extending at an angle upward from said right corner and inward from said right corner toward said central portion.

US Pat. No. 10,653,562

MICRO-POROUS CONDUIT

KCI Licensing, Inc., San...

1. A system for treating a tissue site, comprising:a manifold adapted to be positioned proximate the tissue site;
a sealing drape adapted to cover the manifold and the tissue site to provide a sealed space between the sealing drape and the tissue site;
a porous conduit adapted to be disposed in the sealed space in fluid communication with the manifold and the sealed space, comprising:
a lumen, and
a porous wall, wherein the porous wall has an open porous structure defining a plurality of interconnected pores in fluid communication with one another,
wherein the porous conduit has an insertion end positioned within the sealed space and an external end positioned exterior to the sealed space, and
wherein the external end is coupled in fluid communication to the therapy device; and
a therapy device adapted to be in fluid communication with the porous conduit, comprising:
a reduced-pressure source, and
a pressure sensor, wherein the reduced-pressure source is adapted to be in fluid communication with the lumen and the pressure sensor is adapted to be in fluid communication with the porous wall.

US Pat. No. 10,653,561

TYMPANOSTOMY TUBE DELIVERY DEVICE WITH REPLACEABLE SHAFT PORTION

TUSKER MEDICAL, INC., Me...

1. An apparatus, comprising:a shaft assembly including a plurality of shafts and a plurality of cam followers, each shaft from the plurality of shafts coupled to a different cam follower from the plurality of cam followers;
a handpiece including a housing defining an interior space and a fixed opening extending from an exterior of the handpiece to the interior space, the fixed opening having a dimension greater than a lateral dimension of the shaft assembly such that a portion of each cam follower from the plurality of cam followers can be inserted through the fixed opening into the interior space; and
a drive assembly disposed in the interior space and configured to drive the plurality of shafts in a predetermined sequence to deploy a tympanostomy tube in a tympanic membrane.

US Pat. No. 10,653,560

TRANSPARENT LAMINATE

DEXERIALS CORPORATION, S...

1. A transparent laminate comprising:a transparent substrate; and
a structure layer,
wherein the structure layer contains protrusion portions, depression portions, or both on a surface thereof,
the structure layer comprises a polymerized product of an active energy ray curable resin composition;
the active energy ray curable resin composition comprises a composition of a (meth)acrylate-based polymerizable compound;
the composition of a (meth)acrylate-based polymerizable compound comprises at least any of the following (A) and (B), and the following (C) and (D):
(A) an ester (meth)acrylate of a trihydric alcohol having a main chain and a side chain each comprising an alkyl chain;
(B) an ester di(meth)acrylate of ethylene oxide-modified bisphenol A;
(C) a polyalkylene glycol di(meth)acrylate; and
(D) an ester di(meth)acrylate of a dihydric alcohol having a main chain comprising a linear alkyl chain;
a water contact angle on a surface of the structure layer is 26° or more and 74° or less; and
a storage elastic modulus at 180° C. of the structure layer is less than 0.5 GPa,
when the structure layer has the protrusion portions, an average distance between the protrusion portions adjacent is equal to or less than a wavelength of visible light,
when the structure layer has the depression portions, an average distance between the depression portions adjacent is equal to or less than a wavelength of visible light, and
when the structure layer has the protrusion portions and the depression portions, the average distance between the adjacent protrusion portions and the average distance between the adjacent depression portions is each equal to or less than a wavelength of visible light.

US Pat. No. 10,653,559

SHADING GOGGLES HAVING FUNCTION OF DOUBLE PROTECTION

SERVORE CO., LTD., Gyeon...

2. Goggles, comprising:a goggle body including
a front cover having a front window,
a rear cover having a rear window for coupling to rear side of the front cover,
a lens disposed between the front window and the rear window,
the rear cover having a plurality of protrusions disbursed around front of the rear window with each protrusion corresponding to edge of the lens so the lens is fitted within the protrusions, and
front of the rear window having a plurality of gaps with each gap positioned, respectively, between two of the plurality of protrusions and corresponding to the edge of the lens with the plurality of gaps allowing external air to flow into the goggle body; and
a skirt coupled to rear of the rear cover.

US Pat. No. 10,653,558

OPHTHALMIC KNIFE AND METHODS OF USE

NEW WORLD MEDICAL, INC., ...

1. An ophthalmic knife, comprising:a shaft;
a platform connected to the shaft at a first angle relative to a plane, the platform comprising:
a top surface; and
a bottom surface;
first and second cutting blades disposed in parallel that are separated by a gap and extend from the top surface to the shaft at a second angle relative to the plane, wherein the second angle is different than the first angle; and
a lumen extending through the shaft and terminating at an exit port extending through the bottom surface of the platform.

US Pat. No. 10,653,557

OPHTHALMOLOGICAL LASER THERAPY DEVICE FOR PRODUCING CORNEAL ACCESS INCISIONS

Carl Zeiss Meditec AG, J...

1. An ophthalmological laser therapy device, comprising:a laser system that generates a pulsed laser beam;
a positioning system that spatially displaces a focal volume of the laser beam into a target region;
a control system that controls working parameters of the positioning system, working parameters of the laser system or both the working parameters of the positioning system and the working parameters of the laser system;
wherein the control system is programmed to generate a corneal access incision in corneal tissue of an eye through photodisruption, to modify the working parameters of the laser system, the working parameters of the positioning system or both the working parameters of the positioning system and the working parameters of the laser system as a function of a spatial position of the focal volume of the laser beam in the corneal tissue, such that the access incision varies in terms of width in the corneal tissue or the access incision both varies in terms of the width in the corneal tissue and is interrupted,
wherein the corneal access incision is formed as a passage or tunnel through the cornea from an outer boundary surface of the cornea to an inner boundary surface of the cornea without resection of tissue and through which a small diameter instrument may be inserted.

US Pat. No. 10,653,556

LENSES, SYSTEMS AND METHODS FOR PROVIDING BINOCULAR CUSTOMIZED TREATMENTS TO CORRECT PRESBYOPIA

AMO Groningen B.V., Gron...

1. A pair of intraocular lenses comprising:a first intraocular lens sized and configured for implantation in a first eye of a patient, the first intraocular lens including rotationally symmetric aberrations configured to induce a predetermined amount of one or more fourth or higher order spherical aberrations in said first eye of the patient; and
a second intraocular lens sized and configured for implantation in a second eye of a patient, the second intraocular lens including non-rotationally symmetric aberrations configured to induce a predetermined amount of one or more second or higher order asymmetrical aberrations in said second eye of the patient;
wherein the predetermined amount of one or more fourth or higher order spherical aberrations is induced only in the first eye, and the predetermined amount of one or more second or higher order asymmetrical aberrations is induced only in the second eye; and
wherein the predetermined amount of one or more fourth or higher order spherical aberrations and the predetermined amount of one or more second or higher order asymmetrical aberrations collectively achieve binocular depth of focus.

US Pat. No. 10,653,555

INTRAOCULAR SHUNT INSERTION TECHNIQUES

AQUESYS, INC., Irvine, C...

1. A method of accessing a treatment location within an eye, the method comprising:introducing a needle into the eye through a cornea of the eye;
advancing a bevel of the needle to a location intermediate a superficial layer and a deep layer; and
rotating the bevel to create a space between the superficial layer and the deep layer by tenting the superficial layer away from the deep layer.

US Pat. No. 10,653,554

FLUID EXCHANGE APPARATUS AND METHODS

ForSight Vision4, Inc., ...

1. An exchange device to inject a therapeutic agent into an ocular implant that is at least partially implanted in an eye, the exchange device comprising:a connector configured to reversibly couple to a syringe;
a needle having a proximal end region fixedly coupled to the connector, the needle defining an injection lumen configured for injecting a therapeutic agent into the ocular implant through a distal opening of the needle;
a receiver container coupled to the connector; and
an outer sheath coupled to a distal end region of the receiver container, the outer sheath comprising:
a wall defining an outlet lumen between an inner diameter of the wall and an outer diameter of the needle, the outlet lumen in fluid communication with the receiver container;
a distal tip; and
a plurality of openings extending through the wall of the outer sheath into the outlet lumen,
wherein the receiver container is fixedly coupled to the connector such that the outer sheath is positioned around at least a portion of the needle and the distal opening of the needle is positioned distal to the distal tip of the outer sheath, and
wherein application of positive pressure through the injection lumen by the syringe during injection of the therapeutic agent into the ocular implant displaces, with at least partial separation from the injected therapeutic agent, pre-existing liquid in the ocular implant into the receiver container via the outlet lumen.

US Pat. No. 10,653,553

THERMAL CONTROL SYSTEM WITH FLUID CARTRIDGES

Stryker Corporation, Kal...

1. A thermal control system for controlling a temperature of a fluid delivered to a patient, the thermal control system comprising:a housing comprising a cavity having opposing walls;
a heat exchanger positioned within the housing adjacent the cavity;
a cartridge having opposing surfaces defining a chamber therebetween for housing the fluid, the cartridge adapted to be removably received within the cavity; and
a biasing element incorporated into the cartridge and adapted to bias the opposing surfaces away from one another and into contact with the opposing walls, wherein when the cartridge is received within the cavity, thermal energy is transferred between the heat exchanger and the fluid housed within the cartridge.

US Pat. No. 10,653,552

DEVICE AND METHOD FOR OPENING AN AIRWAY

SOMMETRICS, INC., Vista,...

1. An apparatus for alleviating obstruction of an airway of a user, comprising:(i) a therapy appliance comprising a peripheral surface configured to mate with and thereby enclose an external area of the user's throat overlying the upper respiratory passage of the user, whereby, when mated, said therapy appliance provides a space-filled chamber lying between an inner surface of the therapy appliance and the user's throat having an enclosed variable volume of between 8.19 and 196.64 cm3 (0.5 and 12 in3), wherein said peripheral surface distributes a force load across a sufficient skin area such that pressure along a contact surface with the user's skin does not exceed 60 mm Hg; and
(ii) a housing wearably supported on the therapy appliance and comprising:an air pump which mates directly with the chamber and configured to maintain a partial vacuum of about 7.62 to about 60.96 cm H2O within said chamber,a vacuum control module comprising a microcontroller operatively coupled to motor control circuitry which controls the air pump in a discontinuous fashion and at a variable pumping rate, wherein the vacuum control module is configured to provide a first pumping profile which provides an initial high pumping rate to generate the partial vacuum, and a second pumping profile which provides a reduced pumping rate to compensate for leakage of air into the chamber,a pressure sensor operably connected to the vacuum control module and configured to determine a differential between the chamber partial vacuum and ambient atmospheric pressure and to detect a drop in vacuum that requires energizing the air pump, anda battery providing power to the air pump and vacuum control module.

US Pat. No. 10,653,551

METHODS AND APPARATUSES FOR OSTOMY GAS MANAGEMENT

ENTREMOUS, LLC, San Fran...

1. A gas management apparatus for use with an ostomy pouch, comprising:an insert port defining an insert-receiving passage in communication with an inner chamber of an ostomy pouch and an exterior of the ostomy pouch, the insert port being integrated into one or more walls of the ostomy pouch;
an insert selectively received in the insert-receiving passage of the insert port, the insert including at least one vent therein; and an odor adsorbent element disposed in the insert, the insert-receiving passage and the vent of the insert defining a pathway for gases passing from the inner chamber of the ostomy pouch and through the odor adsorbent element to pass out of the gas management apparatus;
the insert port including an inner wall and an outer wall, said inner and outer walls defining a groove therebetween, the insert including a hub having a wall received in the groove defined between the inner and outer walls of the insert port; and
a latch provided on at least one of the inner and outer walls of the insert port, the latch securing the insert to the port, the latch being defined by a pair of facing ridges formed on facing surfaces of the inner and outer walls defining the groove of the insert port, and the wall of the hub including a ridge that is lockingly engaged by the facing ridges formed on facing surfaces of the inner and outer walls, thereby securing the hub to the insert port.

US Pat. No. 10,653,550

EXTERNAL PENILE ERECTION SYSTEM

1. A penile erection system comprising:a tubular penile sleeve formed of soft elastomeric material having dimensions expandable to accommodate a flaccid or erect penis, the tubular sleeve having a ventral side, a dorsal side, two lateral sides, a substantially funnel-shaped proximal end, and a tapering distal end;
a pair of arcuate balloons embedded in the sides of the penile sleeve;
a dorsal insert on the dorsal side of the penile sleeve, said dorsal insert configured to apply pressure to the dorsal veins of an erect penis;
a ventral insert on the ventral side of the penile sleeve; and
a fiber matrix embedded in said penile sleeve.

US Pat. No. 10,653,549

TOPICAL MEDICATION METHOD FOR ERECTILE DYSFUNCTION

1. A male condom sheath having a closed distal region defined as covering a user's glans penis when situated over and around such a user's penis, and an open proximal region defined as the remainder of said condom having a top edge abutting said bottom edge of said distal region and a bottom edge at the opening of said condom, said condom comprising at least three layers of flexible material within the sheath thereof within said closed distal region, wherein one of said at least three layers is an outer layer for contact with a sexual partner when in use, wherein one of said at least three layers is a material for retention of erectile dysfunction medicament therein for migration therefrom when exposed to heat and friction during a sexual activity, and wherein one of said at least three layers is an inner layer material for erectile dysfunction medicament delivery to the surface of said user's skin; wherein said open proximal region does not comprise said material for retention of erectile dysfunction medicament but does include the same flexible material as said outer layer for contact with a sexual partner when in use; wherein said condom further includes a flexible, pressure ring at the bottom edge of said distal region and a second flexible, pressure ring at the bottom edge of said proximal region.

US Pat. No. 10,653,548

ORTHOPEDIC BRACE WITH MAGNETIC ASSISTANCE

1. An apparatus for assisting a person with a spastic gait, said apparatus comprising:a first support device dimensioned and configured to fit about a left thigh of the person;
a first magnetic device attached to said first support device, said first magnetic device positioned medial to the left thigh when said first support device is worn by the person, said first magnetic device having a first magnetic field;
a second support device dimensioned and configured to fit about a right thigh of the person; and
a second magnetic device attached to said second support device, said second magnetic device positioned medial to the right thigh when second first support device is worn by the person, said second magnetic device having a second magnetic field, said first magnetic field opposing said second magnetic field; and
said first magnetic device and said second magnetic device each includes a matrix containing a powder that is magnetic, said powder distributed with a density that is directly related to a desired magnetic field distribution.

US Pat. No. 10,653,547

TRUNK ORTHOSIS

1. A trunk orthosis, comprising:a bandage designed to be applied ventrally to a patient's trunk;
a support device connected to the bandage and designed to be applied dorsally to the patient's trunk, the support device being designed as a frame with frame portions, the frame portions mounted on each other in an articulated manner or elastically with a hinge, the frame portions being spring-loaded and, in an applied state, being pre-stressed by the bandage, the frame portions including an upper frame part configured to be supported in the area of the patient's thoracic spine and a lower frame part configured to be supported in the area of the patient's lumbar spine;
at least one tightening strap secured to or guided on the hinge and secured to the bandage, the at least one tightening strap being tensioned frontally and configured to apply a force centrally to a pivot axis of the hinge.

US Pat. No. 10,653,546

ORTHOPEDIC DEVICE HAVING A DYNAMIC CONTROL SYSTEM

OSSUR HF, Reykjavik (IS)...

1. An orthopedic device having first and second struts connected to one another by a hinge system including at least one hinge, comprising:a dynamic control system including:
a first dynamic component arranged on a first side of the orthopedic device relative to an anterior-posterior plane, and superior to the hinge system, the first dynamic component connected to at least one of the first and second struts and arranged to exert a first dynamic force directed toward at least one of the first and second struts according to a flexion angle of the hinge system, a first cable consisting of and terminating at first and second ends with the first end securing to the first dynamic component and extending along the first strut and past the at least one hinge inferiorly to the hinge system, the second end of the first cable anchored to the second strut; and
a second dynamic component arranged on a first side of the orthopedic device relative to an anterior-posterior plane, and inferior to the hinge system, the second dynamic component connected to at least one of the first and second struts and arranged to exert a second dynamic force directed toward at least one of the first and second struts according to a flexion angle of the hinge system, a second cable consisting of and terminating at first and second ends with the first end securing to the second dynamic component and the second end anchoring to and terminating at the at least one hinge such that the second end does not extend superiorly past the at least one hinge and engages a corner inlet of the at least one hinge at the anterior and inferior side;
a counterforce system located on a second side of the orthopedic device relative to an anterior-posterior plane and adapted to counteract the first and second dynamic forces with at least one counterforce;
wherein the first and second cables are separate and independently adjustable relative to one another;
wherein the first cable freely extends over the hinge system without interference with movement of the first cable as the hinge system articulates.

US Pat. No. 10,653,545

SLEEVE TUBE AND METHOD OF USE

Kent C. Sasse, Reno, NV ...

1. An orogastric tube comprising:a proximal end section;
a distal working end section opposite the proximal end section, the distal working end section having a preformed, predetermined, flexible, and resilient curved working portion having a predetermined overall ventral curvature angle of 70-145 degrees;
a main body section intermediate the proximal end section and distal working end section;
a sump channel extending from the proximal end section, through the main body section, and into the curved working end section;
a suction channel extending from the proximal end section, through the main body section, and into the curved working end section;the distal working end section having a tubular outer wall surrounding (i) the sump channel section within the distal working end section and (ii) the suction channel section within the distal working end;wherein the curved working portion of the distal working end section includes a preformed, predetermined curved row of flexion reliefs penetrating an outer wall of the curved working portion, wherein said flexion reliefs are configured to allow the outer wall of the curved working portion to bend at a location of said flexion reliefs;
the curved working portion of the distal working end section having a preformed, predetermined curved first row of suction apertures penetrating the outer wall of the distal working end section and in material transfer communication with the suction channel, and (ii) a preformed, predetermined curved second row of suction apertures penetrating the outer wall of the distal working end section and in material transfer communication with the sump channel.

US Pat. No. 10,653,544

RESTRICTION DEVICE

1. A hydraulic implantable restriction device for restricting a luminary organ of a patient, the hydraulic implantable restriction device comprising:a first hydraulic elongated restriction element and forming means for forming the elongated restriction member into at least a substantially closed loop around a first portion of the luminary organ, the first elongated restriction element being adapted to restrict the first portion of the luminary organ, and
a second hydraulic elongated restriction element and forming means for forming the elongated restriction member into at least a substantially closed loop around a second portion of the luminary organ, the second elongated restriction element adapted to restrict the second portion of the luminary organ, and
a hydraulic pump, for pumping fluid from an implantable reservoir to at least one of the first and second restriction elements, the hydraulic pump comprising a hollow member for fluid transportation, and an operable compression member adapted to engage and compress the hollow member, the hydraulic pump being arranged for, upon compression of the hollow member, pumping fluid from one of the first and second restriction elements, via the hollow member, to the other one of the first and second restriction elements, such that operation of the hydraulic pump in a first operational state simultaneously causes the first hydraulic restriction element to restrict the first portion of the luminary organ and the second hydraulic restriction element to release the restriction of the second portion of the luminary organ, and in a second operational state simultaneously causes the first hydraulic restriction element to release the restriction of tile first portion of the luminary organ and the second hydraulic restriction element to restrict the second portion of the luminary organ, and
a control unit adapted to control the hydraulic pump and to control the first and second restriction elements for automatically switching between restricting the first and second portion of the luminary organ, for creating a less damaging restriction, wherein the control unit is adapted to automatically switch between restricting the first and second portion of the luminary organ on a basis of at least one of:
a lapsed time being between 10 minutes and 6 months, andthe patient using a function of the restricted luminary organ.

US Pat. No. 10,653,543

APPARATUS FOR TREATING GERD

1. An apparatus for treating reflux disease of a human patient, the apparatus comprising:a first movement restriction device segment, and
a second movement restriction device segment,
wherein the first movement restriction device segment and the second movement restriction device segment are adapted to be directly connected, in the patient, to each other into an assembled, implantable movement restriction device, and
wherein the first and second movement restriction device segments have a size and shape allowing them to be completely invaginated by a stomach fundus wall portion of the patient and to maintain a predefined shape when assembled and invaginated by the stomach fundus wall portion, without injuring the stomach fundus wall, in a position between the patient's diaphragm and the cardia sphincter, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, wherein the assembled movement restriction device is configured to be disassembled into its movement restriction device segments if the movement restriction device leaves its invaginated stomach position, and wherein the movement restriction device segments are adapted to separately pass through the food passageway, thereby reducing risk for causing obstruction/ileus in the patient's intestine.

US Pat. No. 10,653,542

DEVICE, SYSTEM AND METHOD FOR TREATING OBESITY

1. An obesity treatment device comprising:at least one operable stretching device implantable in an obese patient and adapted to stretch a portion of the patient's stomach wall from the outside thereof, such that a feeling of satiety is actively created, wherein the at least one operable stretching device is adapted to engage the stomach from the outside thereof and comprises a first engaging member configured to engage the stomach wall at a first position on the outside of the stomach and a second engaging member configured to engage the stomach wall at a second position on the outside of the stomach, wherein the first and second engaging members comprises at least one of:
a fixation adapted to be sutured or stapled to the outside of the stomach wall, for fixating the engaging members, and
a body adapted to be invaginated in the stomach wall from the outside thereof, for fixating the engaging members, wherein the device further comprises:
a respective leg connected to each of the first and second engaging members; and
an implantable non-invasive operation device for non-invasively operating the stretching device without any penetration of the stomach wall, when implanted, wherein the fixation or body of the first and second engaging members are connected to the operation device via the respective leg, and wherein the operation device is configured to operate the fixation or body of the first and second engaging member by exerting a force on the respective leg so as to move the first and second engaging members away from each other to stretch the stomach wall portion such that a feeling of satiety is created.

US Pat. No. 10,653,541

STENT DELIVERY ASSEMBLY

COOK MEDICAL TECHNOLOGIES...

1. A stent delivery assembly comprisinga delivery balloon having a balloon axis and a balloon surface with a number of strips durably attached to the balloon surface and extending along the balloon axis, the strips having an unhydrated state and a hydrated state, the strips having a smaller volume in the unhydrated state than in the hydrated state, the strips in the hydrated state being radially indentable and configured to inhibit microsliding of a stent along a surface of the strips by an elastic counterforce, wherein the delivery balloon has a pleated collapsed state with a number of pleats connected to one another via inner folds, the number of pleats being identical to the number of strips, and each pleat having an outer fold, a respective one of the strips being disposed at or on the outer fold and the inner folds being free of strips.

US Pat. No. 10,653,540

BIFURCATED HIGHLY CONFORMABLE MEDICAL DEVICE BRANCH ACCESS

1. A stent graft comprising:a graft having an inward-facing surface and an outward-facing surface;
a stent having undulations defining a first set of apices extending in a first direction and a second set of apices extending in an opposing second direction; and
a tape member extending helically about and being fixedly secured to the graft such that a portion of the tape member covers the first set of apices of the stent to form a series of confined apices in the first direction and a series of unconfined apices in the second direction, whereby the stent graft is configured to be longitudinally compressed to form circumferentially oriented unidirectional pleats along one of the inward-facing and outward-facing surfaces of the graft with the confined apices positioned under an adjacent pleat.

US Pat. No. 10,653,539

ELECTROMAGNETIC ACTUATION MECHANISM FOR INDIVIDUAL DIGIT CONTROL OF AN ARTIFICIAL HAND

1. An apparatus designed for use as a prosthetic or artificial hand comprising:at least one locking mechanism;
an electromagnetic actuation system;
a spline nut and shaft assembly;
a timing belt;
a spline shaft pulley;
a motor; and
a hand configuration.

US Pat. No. 10,653,538

FLUID-DRIVEN BUBBLE ACTUATOR ARRAYS

THE BOARD OF REGENTS OF T...

1. An apparatus comprising:a flexible first layer comprising a substantially flat first portion and a plurality of second portions each protruding away from the first portion to define a chamber, a majority of which is surrounded by a boundary lying on the first portion;
a flexible second layer that is substantially flat; and
where the first layer is sealed in fixed relation to the second layer along the boundaries to define a plurality of cells between the first layer and the second layer in the chambers and such that the first layer has a surface overlying the cells; and
where the apparatus is configured to be coupled to an interior of a helmet.

US Pat. No. 10,653,537

DEVICES AND SYSTEMS FOR POST-FILLING A SPINAL IMPLANT

Pinnacle Spine Group, LLC...

1. A spinal fusion system comprising:an implant comprising a top surface configured to at least partially engage a lower surface of a first vertebral body and a bottom surface configured to at least partially engage an upper surface of a second vertebral body, the second vertebral body being adjacent to the first vertebral body;
wherein the implant comprises an internal chamber, wherein the internal chamber extends from the top surface to the bottom surface of the implant;
wherein the implant comprises at least one passageway extending from an outside of the implant to the internal chamber such that the at least one passageway is in fluid communication with the internal chamber; and
wherein the internal chamber is configured to receive graft material delivered through the at least one passageway;
an implant insertion tool sized and configured to position the implant to a target intervertebral space;
wherein, once the implant is positioned between the first and second vertebral bodies, an upper gap exists between an upper surface of a peripheral boundary of the implant and an adjacent endplate surface of the first vertebral body, and a lower gap exists between a lower surface of the peripheral boundary of the implant and an adjacent endplate surface of the second vertebral body; and
a graft material delivery system configured to deliver a volume of graft material into the internal chamber of the implant, the graft material delivery system comprising a conduit, wherein a volume of graft material is configured to be delivered to the internal chamber of the implant via the conduit;
wherein the internal chamber is configured to contain graft material delivered into the internal chamber such that graft material at least partially contacts endplate surfaces of both the first and the second vertebral bodies and at least partially fills the upper and lower gaps; and
wherein graft material, once directed into the internal chamber, is configured to vertically span across the adjacent endplate surfaces of the first and second vertebral members in order to enhance spinal fusion between the first and second vertebrae; and
wherein the implant is configured such that graft material directed into the internal chamber is configured to vertically span across the adjacent endplate surfaces of the first and second vertebral bodies before graft material laterally exits the peripheral boundary of the implant along an interface of the implant and the adjacent endplate surfaces of the first and second vertebral bodies.

US Pat. No. 10,653,536

MINIMALLY INVASIVE INTERVERTEBRAL SYSTEMS AND METHODS

EIT Emerging Implant Tech...

1. A minimally invasive intervertebral implant for placement between adjacent vertebrae, comprisinga circuitous body defining a luminal axis extending longitudinally therethrough, the circuitous body comprising a plurality of segments linked by living hinges configured to deform in transition from an open position to a closed position, at least one of the living hinges includes a locking mechanism on adjacent hinged segments comprising a male fitting configured to engage a female fitting to lock the hinge,
proximal and distal ends oppositely disposed along a lateral axis of the circuitous body, wherein:
in a first configuration the proximal and distal ends are at a maximum separation and the living hinges are in the open position;
in a second configuration wherein the proximal and distal ends are closer together than in the first configuration, and the living hinges are in the closed position; and
wherein a transition from the first configuration to the second configuration deforms the circuitous body and the engagement of the male and female fittings are configured to maintain the second configuration subsequent to the transition.

US Pat. No. 10,653,535

APPARATUS AND METHOD FOR BONE SCREW DEPLOYMENT

Providence Medical Techno...

1. A deployment guide system comprising: an implant comprising:a top surface and a proximal end including an opening, wherein at least a portion of the opening extends through the implant at an angle relative to the top surface such that when a bone anchor is used, the bone anchor extends through the opening; and
a deployment guide comprising:
a guide shaft having a lumen extending between a proximal end and a distal end;
an elongated tube extending through at least a portion of the guide shaft lumen and protruding from a distal tip of the guide shaft;
a guide passage extending through a lumen of the elongated tube;
a channel formed from one or more surfaces at a distal end of the guide passage, the channel being oriented at an angle relative to the guide passage;
a window disposed at a distal end of the channel, the window providing an opening in the elongated tube to the guide passage, the channel and the guide passage forming a deployment trajectory through the window,wherein the elongated tube interfaces with the proximal end of the implant, such that the window is oriented relative to the opening in the implant.

US Pat. No. 10,653,534

ACETABULAR CUP DETACHING APPARATUS FOR ARTIFICIAL HIP JOINT

IMEDICOM, Gunpo-si, Gyeo...

1. An acetabular cup detaching apparatus for an artificial hip joint comprising:a body part that rotates with power transmitted thereto; and
a cutting part configured to be brought into close contact with an inner circumferential surface of the acetabular cup and rotating together with the body part to cut a surface of an acetabular bone to which an acetabular cup is attached,
wherein the body part comprises:
a rotary shaft part formed in a tubular shape that is rotated with power transmitted thereto and having the cutting part coupled to one side; and
a housing part surrounding a perimeter of the rotary shaft part, and wherein the cutting part comprises:
a pivoting cutter coupled to the rotary shaft part and configured to be brought into close contact with an inner circumferential surface of the acetabular cup, rotated together with the rotary shaft part in a radial direction of the acetabular cup, and simultaneously rotated along an outer circumferential surface of the acetabular cup to cut a surface of the acetabular bone to which the acetabular cup is attached;
a slide moving part disposed slidably on an inner side of the rotary shaft part and moved forward to rotate the pivoting cutter by a predetermined angle while the rotary shaft part is rotating; and
an angle adjusting part disposed within the housing part to cause the slide moving part to be slide by a predetermined distance and adjust an angle of rotation of the pivoting cutter.

US Pat. No. 10,653,533

ASSEMBLER FOR MODULAR PROSTHESIS

Kambiz Behzadi, Pleasant...

1. An adapter for a modular prosthesis head, the head defining a trunnion bore having a trunnion installation axis, an outer spherical perimeter surface, and a planar face symmetric about the trunnion installation axis, the planar face opposite of the outer spherical perimeter surface, comprising:an anvil body defining a top planar surface, a bottom planar surface spaced apart from and parallel to said top planar surface, a circumferential channel in an outer surface of said anvil body disposed between and parallel to said planar surfaces, an anvil axis extending through and perpendicular to said planar surfaces and a spherical depression defined in said top surface with said spherical depression conforming to, and configured to mate with, the outer spherical perimeter surface;
an anvil axis interaction structure defined in said bottom surface with said anvil axis interaction structure symmetric about said anvil axis; and
a shell, enclosing said anvil body, said shell defining a shell planar portion, a sidewall having an interior circumferential ledge complementary to and disposed within said circumferential channel with said circumferential ledge spaced apart from and parallel to said shell planar portion and said sidewall further defining a shell cavity;
wherein said shell further defines a shell alignment axis when the modular prosthesis head is installed in said depression and both the modular prosthesis head and anvil are installed in said shell cavity with said shell alignment axis non-rotatingly aligned with the trunnion installation axis and with said anvil axis responsive to an engagement of said shell with both said anvil body and the planar face.

US Pat. No. 10,653,532

INTERVERTEBRAL PROSTHESIS OR DISK PROSTHESIS

DePuy Synthes Products, I...

1. A surgical method, comprising:implanting a first intervertebral spacer in a disc space defined between an upper vertebra and a lower vertebra, wherein the first spacer comprises:
an upper side in contact with at least a portion of the upper vertebra;
a lower side in contact with at least a portion of the lower vertebra;
an anterior side facing towards an anterior portion of the disc space;
a posterior side facing towards a posterior portion of the disc space;
a first lateral side extending between the upper and lower sides and between the anterior and posterior sides; and
a second lateral side extending between the upper and lower sides and between the anterior and posterior sides;
implanting a second intervertebral spacer in the disc space defined between the upper vertebra and the lower vertebra, wherein the second spacer comprises:
an upper side in contact with at least a portion of the upper vertebra;
a lower side in contact with at least a portion of the lower vertebra;
an anterior side facing towards the anterior portion of the disc space;
a posterior side facing towards the posterior portion of the disc space;
a first lateral side extending between the upper and lower sides and between the anterior and posterior sides; and
a second lateral side extending between the upper and lower sides and between the anterior and posterior sides;
wherein the first and second spacers are positioned such that the second lateral side of the first spacer faces the first lateral side of the second spacer;
wherein the first and second spacers are spaced a distance apart from one another; and
conveying a volume of flowable material to the first spacer, the flowable material flowing into an inlet opening of the first spacer, through a cavity of the first spacer, out of at least one of the first and second lateral sides of the first spacer, and into a central region of the disc space disposed between the first and second spacers,
wherein a greater amount of the flowable material emerges from one of the first and second lateral sides of the first spacer than from an opposing lateral side of the first spacer.

US Pat. No. 10,653,531

PROSTHETIC DEVICE

WERNER CONSULTING AG, Wo...

1. A prosthetic device for replacing at least one vertebral body, the prosthetic device being expandable from a fully collapsed state to a fully expanded state and havingan anterior end and a posterior end which are located on opposite sides of a vertical frontal plane;
a proximal end and a distal end which are located on opposite sides of a vertical midsagittal plane arranged perpendicular to the frontal plane; and
a top end and a bottom end which are located superiorly and inferiorly of a horizontal transverse plane, respectively,wherein the prosthetic device further comprisesan upper endplate having a top surface that is located at the top end and is configured to abut against a first vertebral body,
a lower endplate having a bottom surface that is located at the bottom end and is configured to abut against a second vertebral body, and
an expandable support structure extending between the upper and lower endplates, said expandable support structure being configured to displace the two endplates relative to one another along a longitudinal axis of the prosthetic device and to hold the two endplates at an axial distance that is measured between the top surface of the upper endplate and the bottom surface of the lower endplate and corresponds to the height of at least half a vertebral body and one intervertebral disc,
wherein the expandable support structure includes an anterior post and a posterior post, each post having an upper end hingedly connected to the upper endplate and a lower end hingedly connected to the lower endplate and each post having a length which is defined by the axial distance between the upper end and the lower end of the respective post,
wherein the length of each post is individually adjustable and is lockable independently from one another to hold the two endplates with an inclination of 0° to 40° relative to each other,wherein the prosthetic device further comprises at least one upper shaft and at least one lower shaft, wherein the upper shaft hingedly connects the upper endplate with the upper ends of the posts, the lower shaft hingedly connects the lower endplate with the lower ends of the posts, and the upper and lower shafts are arranged essentially parallel to one another and are oriented such that their longitudinal axes extend essentially parallel to the frontal plane or the sagittal plane.

US Pat. No. 10,653,530

EXPANDABLE VERTEBRAL BODY REPLACEMENT DEVICE AND METHOD

MUSC Foundation for Resea...

1. A vertebral body device, comprising:a body with a first end and a second end, wherein the body further comprises:
an opening extending from the first end to the second end;
at least one first channel recessed into an interior surface of the body and extending from the first end toward the second end and positioned adjacent to the opening; and
at least one second channel recessed into the interior surface of the body and extending from the second end toward the first end and positioned adjacent to the opening;
a first rotating member rotatably coupled directly to an exterior surface of the first end;
a second rotating member rotatably coupled directly to an exterior surface of the second end;
a first extension member moveably coupled to the first end and engaging an interior surface of the body; and
a second extension member moveably coupled to the second end and engaging the interior surface of the body.

US Pat. No. 10,653,529

JOINT ARTHROPLASTY SYSTEMS, METHODS AND COMPONENTS

FOOT INNOVATIONS, LLC., ...

1. A system for use in a joint arthroplasty for modifying a subtalar joint, the system comprising:a first implant component comprising a first convex surface and a third surface;
a second implant component defining a second concave surface and a fourth surface; and
an insert configured to be inserted in the subtalar joint between the first implant component and the second implant component, the insert comprising
a fifth surface,
an insert shoulder configured to releasably engage with a corresponding recess structure of one of the first implant component or the second implant component, the recess structure including a pair of sidewalls extending along edges of one of the third surface of the first implant component or the fourth surface of the second implant component, the recess structure including a recess wall extending between the recess sidewalls along a length of the insert, the length greater than a width of the insert along which the pair of sidewalls extend, each recess sidewall defining a groove, the insert shoulder including a pair of shoulder walls configured to be releasably received by the pair of recess sidewalls, and
a sixth articulating surface configured to articulate with the other of the third surface of the first implant component or the fourth surface of the second implant component.

US Pat. No. 10,653,528

TOTAL ANKLE REPLACEMENT PROSTHESIS

Integra LifeSciences Corp...

1. A tibial implant comprising:an outer perimeter such that, upon proceeding counterclockwise around said perimeter as viewed from above along a vertical axis, said outer perimeter further comprises a first straight edge;
said first straight edge being followed by a first convex corner that meets and is tangent to said first straight edge;
said first convex corner being followed by a second straight edge or shallow arc that meets and is tangent to said first convex corner,
wherein an angle of said first convex corner is greater than 90 degrees but less than 180 degrees;
said second straight edge or said shallow arc being followed by a second convex corner that meets and is tangent to said second straight edge or said shallow arc;
said second convex corner being followed by a first concave curve, wherein said second convex corner transitions to said first concave curve;
wherein there is a first tangent line that is parallel to said first straight edge and is tangent to said second convex corner at a first tangency point; wherein said first concave curve continues on from said second convex corner to become farther from said first straight edge than is said first tangent line; and
wherein said first concave curve is followed by a convex curve that proceeds from said first concave curve to cross said first tangent line and returns to said first straight edge to form a complete perimeter of said tibial implant.

US Pat. No. 10,653,527

CERAMIC WITH METAL/ALLOY COATING

CERAMIC MEDICAL PRODUCTS,...

1. An article of manufacture comprising a fired magnesium oxide stabilized zirconia ceramic body having a highly smooth surface of said zirconia, which highly smooth surface is at least as smooth as an about 2-Ra micro-inch finish; and, directly on at least part of said highly smooth surface, a metal or metal alloy coating—wherein:said coating is from a metal other than tantalum or a metal alloy other than of tantalum;
said coating is a macro coating less than about 0.014 of an inch in thickness; and
said coating resists being pulled or sheared off the fired magnesium oxide stabilized zirconia ceramic body to a value of about 2,000 pounds or more of force.

US Pat. No. 10,653,526

PROSTHETIC IMPLANT SUPPORT STRUCTURE

Zimmer, Inc., Warsaw, IN...

1. An acetabular system implantable in an acetabular cavity in a patient, comprising:an acetabular cup implant; and
a support component for occupying an area in the acetabular cavity, the support component connected to the acetabular cup implant for supporting the acetabular cup implant in the acetabular cavity, the support component including an outer surface for facing an inner surface of the acetabular cavity and an interior into which only part of the acetabular cup implant is received, the support component being formed separately from the acetabular cup implant for subsequent connection to the acetabular cup implant, the support component capable of being impacted, by itself, into the acetabular cavity for obtaining a press fit of the support component in the acetabular cavity, the support component being formed with a porous metal material that is a bone ingrowth-receptive material with a porous structure for allowing bone of the patient to grow into and throughout the support component for restoring lost bone stock in the acetabular cavity in the area occupied by the support component when the support component is implanted in the acetabular cavity.

US Pat. No. 10,653,525

PENILE IMPLANT

Boston Scientific Scimed,...

1. A medical implant (100, 200), for example a penis implant, comprising:a sheath (110, 210) defining a lumen (222);
which sheath (110, 210) further defines a window or opening (211, 213) in the sheath (110, 210)
a cable member (130, 230) disposed within the lumen of the sheath (110, 210); and
a tensioner (150, 250) engaged with the cable member (130, 230) for applying tension to the sheath (110, 210) so that the sheath (110, 210) is selectively arrangeable between a first tensioned configuration and second non-tensioned configuration,
wherein the tensioner (150, 250) comprises a bias member (254), for providing a bias to the tensioner (150, 250),
wherein the tensioner (150, 250) comprises a release member (258, 260), the release member (258, 260) being moveable between a tension retention position, wherein tension is retained in the sheath (110, 210), and a tension release position, wherein tension is released from the sheath (110, 210),
wherein the release member (258, 260) is accessible and operable through the window or opening (211, 213) in the sheath (110, 210), whereby a portion of the release member (258, 260) is extendible through the window or opening (211, 213) in the sheath (110, 210).

US Pat. No. 10,653,524

DEVICE, SYSTEM, AND METHOD FOR TRANSCATHETER TREATMENT OF VALVULAR REGURGITATION

Polares Medical Inc., Pa...

1. A coaptation assistance element delivery system for treating mal-coaptation of a heart valve, the heart valve having an annulus, the coaptation assistance element delivery system comprising:a coaptation assistance element comprising a first surface and an opposed second surface, each surface bounded by a first lateral edge, a second lateral edge, an inferior edge, and a superior edge, the coaptation assistance element comprising a hub;
a first anchor disposed within a first anchor housing, the first anchor configured to extend through the hub to engage the annulus; and
a release wire extending through the first anchor housing and configured to be positioned adjacent to the annulus.

US Pat. No. 10,653,523

SYSTEMS, METHODS AND DEVICES FOR DELIVERY SYSTEMS, METHODS AND DEVICES FOR IMPLANTING PROSTHETIC HEART VALVES

4C Medical Technologies, ...

1. A method of delivering a self-expanding prosthetic mitral valve device comprising prosthetic mitral valve leaflets to an implantation site within a left atrium of a patient's heart, comprising:accessing the left atrium with a delivery catheter having a proximal end, a distal end and a lumen therethrough;
loading the self-expanding prosthetic mitral valve device in a collapsed configuration into the lumen of the delivery catheter at the proximal end thereof, wherein the collapsed configuration of the prosthetic mitral valve device comprises a prosthetic mitral valve attached thereto;
delivering the collapsed prosthetic valve out of the distal end of the delivery catheter and into the left atrium at a location proximate the implantation site;
allowing the delivered self-expanding prosthetic mitral valve device to expand within the left atrium at the implantation site, wherein at least a portion of the expanded device engages at least a portion of the upper annular surface within the left atrium; and
ensuring that the left ventricle, the annular tissue below or downstream of the upper annular surface and the native mitral valve leaflets of the heart are not touched at any point in the delivery of the self-expanding prosthetic mitral valve device before the delivered self-expanding prosthetic mitral valve device is allowed to expand within the left atrium;
providing a plug attached directly to a side portion of the collapsed self-expanding prosthetic mitral valve device;
aligning the plug with the left atrial appendage; and
engaging the left atrial appendage with the plug when the self-expanding prosthetic mitral valve device is expanded.

US Pat. No. 10,653,522

PROXIMAL TAB FOR SIDE-DELIVERED TRANSCATHETER HEART VALVE PROSTHESIS

VDYNE, INC., Maple Grove...

1. A method for delivering a prosthetic heart valve to an annulus of a native valve between a ventricle and an atrium of a heart, the method comprising the steps:(i) disposing in the atrium of the heart a distal portion of a delivery catheter having a lumen and a longitudinal axis, with a distal end of the delivery catheter directed towards the annulus of the native valve, the distal portion of the delivery catheter having disposed within the lumen thereof the prosthetic heart valve in a compressed configuration,
wherein the compressed configuration of the prosthetic heart valve has a long-axis substantially parallel to a length-wise cylindrical axis of the delivery catheter,
wherein the expanded configuration of the prosthetic heart valve has a height of about 5-60 mm and a diameter of about 25-80 mm,
wherein the prosthetic heart valve comprises an annular support frame having a flow control component mounted within the annular support frame and configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve,
wherein the annular support frame is self-expanding or balloon-expandable,
a distal anchoring tab is mounted on a distal side of the annular support frame, the distal anchoring tab having a length of 10-40 mm, the distal anchoring tab extending laterally from the annular support frame and is configured to be disposed on a ventricle side of the annulus of the native valve when the annular support frame is disposed within the annulus,
at least one proximal anchoring tab is mounted on a proximal side of the annular support frame, the proximal anchoring tab having a length of 2-25 mm, the at least one proximal anchoring tab extending laterally from the annular support frame and is configured to be disposed on the ventricle side of the annulus of the native valve when the annular support frame is disposed within the annulus;
(ii) partially releasing the prosthetic heart valve from the delivery catheter, and positioning the distal anchoring tab at a distal subannular anchoring area, wherein positioning the distal anchoring tab holds the prosthetic heart valve at a raised angle of at least 30 degrees to a localized annular plane relative to a horizontal axis of the valve, and
wherein partially releasing the prosthetic heart valve permits blood to flow partially around the prosthetic heart valve and through the native leaflets, and partially through the flow control component of the prosthetic valve to provide a gradual blood flow transition from flow through native leaflets to complete flow through the prosthetic valve,
wherein the distal subannular anchoring area is a right ventricular outflow tract (RVOT) of a right ventricle or is a sub-annular area below an A1-P1 antero-lateral commissure of a mitral valve;
(iii) completing release of the entire prosthetic heart valve from within the lumen of the delivery catheter, and seating the prosthetic heart valve in the native annulus by applying a downward force in the direction of the ventricle; and
(iv) seating the proximal anchoring tab at a proximal subannular anchoring area.

US Pat. No. 10,653,521

PROSTHETIC VALVES WITH MECHANICALLY COUPLED LEAFLETS

1. A prosthetic valve comprising:a plurality of leaflets, each leaflet having a leaflet attachment region and a leaflet free edge;
a leaflet frame defining an annular shape having one or more leaflet frame edges, the leaflet frame having a plurality of leaflet frame projections extending from at least one of the leaflet frame edges, each of the leaflet frame projections extending at least partially through the leaflet attachment region; and
one or more restraining elements configured to impede decoupling of the leaflets from the leaflet frame, wherein the leaflet attachment region defines a plurality of leaflet apertures spaced apart from each other, each of the leaflet frame projections extending at least partially through a corresponding one of the plurality of leaflet apertures, wherein the one or more restraining elements are coupled to or unitary with the leaflet frame projections configured to impede decoupling of the leaflets from the leaflet frame, wherein the restraining element is integral to each of the leaflet frame projections, wherein the restraining element includes a projection head portion.

US Pat. No. 10,653,520

METHOD OF PREPARING A TISSUE SWATCH FOR A BIOPROSTHETIC DEVICE

St. Jude Medical, Cardiol...

1. A method of manufacturing a bioprosthetic device, comprising:a. producing a tissue swatch having more than one desired thickness by sectioning a tissue sheet on a cryocutting apparatus having a straight blade and a contoured specimen disk, wherein said tissue sheet is suitable for use in the manufacture of said bioprosthetic device, and wherein said contoured specimen disk includes one of an elevated region that produces a depressed thickness of said tissue swatch or a depressed region that produces an elevated thickness of said tissue swatch;
b. cutting said tissue swatch into a shape; and
c. incorporating said shaped tissue swatch into said bioprosthetic device.

US Pat. No. 10,653,519

MITRAL REPAIR AND REPLACEMENT DEVICES AND METHODS

Mitral Valve Technologies...

1. A method for delivering an implant to reshape a native mitral valve of a heart, the implant comprising a coiled anchor having a first end, a second end, and a central axis extending between the first and second ends, wherein the coiled anchor defines an inner space coaxial with the central axis and comprises a first turn defining a central portion of the inner space having a first width, a second turn connected to the first turn at the first end of the coiled anchor and defining a portion of the inner space having a width that is smaller than the first width, and a third turn connected to the first turn at the second end of the coiled anchor and defining another portion of the inner space having a width that is smaller than the first width, and a stent comprising an expandable frame, the method comprising:positioning the coiled anchor at a native mitral valve of a heart of a patient, such that at least a portion of the first turn of the coiled anchor is positioned in a left ventricle of the heart and around valve leaflets of the native mitral valve;
positioning the stent at the native mitral valve through the inner space of the coiled anchor when the stent is in a collapsed state; and
expanding the stent, wherein the stent is expandable to a width that is greater than the width of the inner space defined by at least one of the second turn or the third turn when the coiled anchor is unbiased, such that a radially outward pressure is applied by the stent on the at least one of the second turn or the third turn to increase the width of the portion of the inner space defined by the at least one of the second turn or the third turn, while the width of the portion of the inner space defined by the first turn is decreased to a width that is smaller than the first width.

US Pat. No. 10,653,518

METHODS OF MAKING A DURABLE MULTI-LAYER HIGH STRENGTH POLYMER COMPOSITE SUITABLE FOR PROSTHETIC VALVES

1. A method of making a leaflet of a prosthetic valve, the method comprising:providing a composite material having a fluoropolymer layer having a plurality of pores and an elastomer or elastomeric material resent in the pores of the fluoropolymer layer, the composite material having a predetermined matrix tensile strength that is greater in a first direction relative to a second direction that is orthogonal to the first direction;
arranging the composite material to define at least two overlapping adjacent layers of the composite material, the at least two overlapping adjacent layers of the composite material being oriented such that the first direction of each layer is generally parallel to each other;
bonding the respective adjacent layers of the composite material together via the elastomer or elastomeric material forming a leaflet construct; and
cutting the leaflet construct to form a leaflet having a leaflet width and a leaflet length that is orthogonal to the leaflet width, the leaflet length extending in a flow direction, wherein the first direction of the composite material is parallel with the leaflet width.

US Pat. No. 10,653,517

ADJUSTABLE IMPLANT

MENTOR WORLDWIDE LLC, Ir...

1. An adjustable implant, comprising:a shell including a base and having a first diameter in a plane parallel to the base, the shell further including a first membrane,
a hydraulic mechanism disposed within the shell, the mechanism including a first component and a second component that is moveable with respect to the first component; and
a band disposed within the shell in a round configuration having a second diameter in the plane that is less than the first diameter, the band having a first end and a second end,
wherein the first end of the band is connected to the first component and the second end of the band is connected to the second component,
wherein the mechanism includes a fluid and a pump having a first actuator comprising a first chamber and a second actuator comprising a second chamber, and
wherein the first component comprises a barrel and the second component comprises a piston disposed at least partially within the barrel, and wherein the piston further includes a plunger rod and a plunger cap and the barrel further includes a barrel cap, a first port, and a second port.

US Pat. No. 10,653,516

ELECTROMAGNETIC ARTIFICIAL MUSCLE

The Government of the Uni...

1. An artificial muscle including:an internal electromechanically charged rod moveably extending between a first attach point and a second attach point;
a plurality of mesh cylinders having a mesh cylinder top and a mesh cylinder bottom;
a plurality of fibers surrounding the mesh cylinders having a plurality of connectors mechanically connecting the fibers to the mesh cylinders and wherein
an electromagnetic source activates the artificial muscle through at least one microprocessor to electromechanically create a mesh cylinder movement.

US Pat. No. 10,653,515

TENDON REPAIR APPARATUS AND METHOD

MEDSTAR HEALTH, Columbia...

1. A tendon repair apparatus, comprising:a tendon bridge having oppositely disposed proximal and distal bridge ends spaced longitudinally apart by a bridge body;
a plurality of engagement legs, each engagement leg having a proximal leg end attached directly to a corresponding one of the proximal and distal bridge ends and a distal leg end spaced transversely apart from the tendon bridge; and
at least one receiver plate, transversely spaced from the tendon bridge and extending substantially longitudinally and laterally parallel to the tendon bridge, the receiver plate including a plurality of receiver apertures, each receiver aperture corresponding to a selected engagement leg, and each receiver aperture being configured to selectively engage with a corresponding selected engagement leg, engagement between the receiver aperture and the engagement leg maintaining the receiver plate in transversely spaced indirect connection with the tendon bridge;
the receiver plate being indirectly connected to the tendon bridge only by at least one engagement leg.

US Pat. No. 10,653,514

COLLAGEN FIBER RIBBONS WITH INTEGRATED FIXATION SUTURES AND METHODS OF MAKING THE SAME

MiMedx Group, Inc., Mari...

1. A method of making a medical ribbon, comprising:providing a plurality of fibers, wherein the plurality of fibers are continuous length cross-linked collagen fibers;
forming the plurality of fibers into yarns;
providing at least one suture;
providing the yarns as warp yarns and one or more weft yarns; and
weaving the warp yarns and the one or more weft yarns together to form a ribbon body with a length while crossing the one or more weft yarns over a top of the at least one suture at intervals along the length of the ribbon body to attach the at least one suture to the ribbon body, wherein the at least one suture has at least one tail end that extends a distance of at least about 1 inch off at least one end of the ribbon body, wherein some of the plurality of fibers are cross-linked with a first agent and some of the plurality of fibers are cross-linked with a second agent that is different than the first agent.

US Pat. No. 10,653,513

BARORECEPTOR TESTING PRIOR TO IMPLANTATION METHODS AND APPARATUS

Vascular Dynamics, Inc., ...

1. A method of screening a subject for a therapy, the method comprising:providing at least one mechanical stimulus to a blood vessel, the at least one mechanical stimulus generating at least a first region of the blood vessel having increased radius of curvature and at least a second region of the blood vessel having decreased radius of curvature, wherein the at least one mechanical stimulus is provided intra-vascularly, and wherein providing the at least one mechanical stimulus comprises advancing a mechanical stimulus device through vasculature of the subject to a target location;
detecting at least one change in at least one physiological parameter in response to the provided at least one mechanical stimulus; and
selecting an implant to provide the therapy to the subject based on the detected at least one change in the at least one physiological parameter, wherein at least the first region of the blood vessel having increased curvature comprises a plurality of first regions having increased radius of curvature, wherein at least the second region of the blood vessel having decreased curvature comprises a plurality of second regions having decreased radius of curvature, and wherein the first and second regions alternate with one another around a circumference of the blood vessel.

US Pat. No. 10,653,512

ELECTROSPUN PTFE COATED STENT AND METHOD OF USE

Merit Medical Systems, In...

1. A stent, comprising:a first layer of electrospun polytetrafluoroethylene (PTFE) fibers,
a second layer of electrospun PTFE fibers, wherein the first and second layers have different porosities,
a tie layer disposed between the first and second layers of electrospun PTFE fibers, wherein the tie layer is a non-porous fluorinated ethylene propylene (FEP) film that is impermeable to tissue ingrowth, wherein the film continuously extends to cover the first layer from a first layer proximal end to a first layer distal end; and
a scaffolding structure configured to resist radial compression when disposed in a lumen of a patient;
wherein the scaffolding structure comprises two longitudinal portions of different compressibilities.

US Pat. No. 10,653,511

ELECTROSPUN PTFE COATED STENT AND METHOD OF USE

Merit Medical Systems, In...

1. A stent, comprising:a first layer of electrospun polytetrafluoroethylene (PTFE) fibers, the first layer configured to permit tissue growth on the first layer;
a second layer of electrospun PTFE fibers;
a tie layer disposed between the first layer of electrospun PTFE fibers and the second layer of electrospun PTFE fibers, wherein the tie layer comprises fluorinated ethylene propylene (FEP) film that is not electrospun, wherein the tie layer is impervious to tissue growth through the tie layer, and wherein the film continuously extends to cover the first layer from a first layer proximal end to a first layer distal end; and
a cuff adjacent an end of the stent, wherein the cuff comprises a third layer of electrospun PTFE fibers configured to promote rapid cellular ingrowth into the cuff, and wherein the third layer is separate from the first and second layers.

US Pat. No. 10,653,510

STENT INCLUDING DISPLACEMENT CAPABILITIES

BOSTON SCIENTIFIC SCIMED,...

20. A method of treating the esophagus, the method comprising:advancing a medical device to a target site within the esophagus, the medical device including:
an expandable scaffold having a first end region and a second end region opposite the first end region; and
a support member extending circumferentially around and attached to an outer surface of the expandable scaffold at a position between the first and second end regions of the expandable scaffold;
radially expanding the scaffold and the support member to an expanded state such that the support member is positioned between an inner surface of the esophagus and an outer surface of the stent in the expanded state; and
moving at least a portion of the support member in the expanded state axially relative to the inner surface of the esophagus, wherein moving the support member axially moves the scaffold longitudinally from a first position within the esophagus to a second position to accommodate peristalsis in the esophagus, wherein the first and second end regions of the expandable scaffold extend axially beyond an entirety of the support member in both the first and second positions.

US Pat. No. 10,653,509

HOLDER FOR HEART VALVE PROSTHESES, CORRESPONDING STORAGE ARRANGEMENT, DELIVERY INSTRUMENT AND KIT

Sorin Group Italia S.r.l....

1. A holder coupleable to a delivery instrument for expandable heart valve prostheses, the delivery instrument including a handle, a delivery sheath displaceable along a longitudinal axis of the delivery instrument, and a shaft including a connector member coupleable to the holder, the holder comprising:a hub portion having a longitudinal axis, a proximal end, and a distal end;
an engagement portion coupled to the hub portion and including a plurality of finger members variably positionable relative to the hub portion between a collapsed condition, wherein at least some of the plurality of finger members are closed onto the hub portion, and an expanded condition, wherein the plurality of finger members radially protrude with respect to the hub portion for engaging a heart valve prosthesis, wherein one or more of the plurality of finger members are L-shaped and include a body portion and a distal portion located at a distal end of the body portion, the body portion having a proximal end connected to the hub portion and a first thickness from the proximal end to the distal end, and the distal portion having a second thickness that is greater than the first thickness to define an axial abutment surface for the heart valve prosthesis; and
a plurality of radially protruding formations coupled to the distal end of the hub portion and configured to engage and hold the distal portion of each of the plurality of finger members in the collapsed condition and to be unengaged with the distal portion of each of the plurality of finger members in the expanded condition;
wherein, with the delivery sheath in a fully retracted position, the holder is configured for coupling to a prosthetic heart valve, and the delivery sheath is displaceable axially towards an advanced position, whereby the relative movement between the delivery sheath and the holder is configured to cause a radial contraction of at least one of the finger members together with the heart valve prosthesis and loading of the heart valve prosthesis into the delivery sheath.

US Pat. No. 10,653,508

TEXTILE-BASED PROSTHESIS FOR TREATMENT OF INGUINAL HERNIA

1. A prosthesis for the repair of an inguinal hernia, of generally elongate shape defining a longitudinal axis aligned on a medial-lateral axis and a transversal axis aligned on a cranial-caudal axis comprising:at least one flexible biocompatible textile of elongate shape comprising a medial end, a lateral end, a cranial part and a caudal part, the textile delimited by a peripheral outer edge formed of a convex medial edge, a convex cranial edge, a convex lateral edge and a caudal edge, and,
at least one reinforcing element for the textile, the reinforcing element in the form of a resilient frame connected to the textile and set back from the peripheral outer edge, wherein the frame comprises a convex cranial segment extending from the medial end of the textile to the lateral end of the textile along the convex cranial edge, a caudal segment substantially extending from the medial end of the textile to the
lateral end of the textile and caudally spaced with respect to the convex cranial segment, a lateral corner segment joining together the convex cranial segment and the caudal segment in the lateral end of the textile, a folding segment configured for joining a medial end of the convex cranial segment to a point located on the caudal segment while leaving a region of the medial end of the textile free of any frame, and a caudal extension located on the caudal segment and extending in a caudal direction toward the caudal edge of the textile.

US Pat. No. 10,653,507

EXPANDING ABSORBABLE TACK

Covidien LP, Mansfield, ...

1. A surgical system comprising:a delivery device; and
a surgical fastener loaded within the delivery device, the surgical fastener including:
a head section including an arm member pivotably disposed on an outer surface of the head section, the arm member configured to pivot radially outward from the outer surface of the head section, wherein a distal surface of the arm member extends along a first plane spaced apart from a second plane defined by a distal surface of the head section, the arm member including a fixed end and a free end, wherein the fixed end is connected to the head section between a distal end and a proximal end of the head section; and
a tissue snaring section defining a longitudinal axis and extending away from the head section, the tissue snaring section having an outer surface defining at least one helical thread.

US Pat. No. 10,653,506

IMPLANT UNIT

1. An implant unit comprising:a fixture configured to assemble to an alveolar bone and comprises a long hole therein;
an intermediate structure inserted to the long hole of the fixture;
an abutment having a lower portion assembled to an upper-end portion of the intermediate structure, wherein the lower portion of the abutment includes a groove having a shape corresponding to the upper-end portion of the intermediate structure; and
an assembling element configured to couple the intermediate structure with the abutment through an assembling groove,
wherein a lower portion of an inner sidewall of the fixture has a sloped surface, a lower portion of the intermediate structure has a sloped surface, and at least a portion of the sloped surface of the long hole and at least a portion of the sloped surface of the intermediate structure contact each other,
wherein a stepped portion is provided on the inner sidewall of the fixture, and a counter-stepped portion corresponding to the stepped portion is provided on a sidewall of the intermediate structure,
wherein at least one or more gaps are formed between the fixture and the intermediate structure to loosen assembly between the intermediate structure and the fixture,
wherein the at least one or more gaps comprises:
a first gap between an under part of the stepped portion of the fixture and an under part of the counter-stepped portion of the intermediate structure; and
a second gap between an upper portion of the inner sidewall of the fixture and the sidewall of the intermediate structure,
wherein the upper portion of the inner sidewall of the fixture has a sloped surface so that a width of the second gap increases gradually toward an utmost portion of the second gap and the utmost portion of the second gap is opened between the sidewall of the intermediate structure and the inner sidewall of the fixture,
wherein the fixture and the intermediate structure are coupled with each other by a first structure formed at a lower-end portion of the intermediate structure and a second structure formed on the inner sidewall of the fixture that accommodates the first structure,
wherein the lower-end portion of the intermediate structure is divided into a plurality of pieces,
wherein the assembling groove extends to the lower-end portion of the intermediate structure,
wherein the assembling element is a shortened assembling element which does not reach the lower-end portion of the intermediate structure such that the first structure of the intermediate structure is elastically coupled with the second structure of the fixture.

US Pat. No. 10,653,505

SELF-LIGATING BRACKET

American Orthodontics Cor...

1. A self-ligating bracket comprising:a bracket body having a first side opposed from a second side and an arch wire slot that extends across the bracket body from the first side to the second side; and
a spring clip comprising a first arm comprising a first arm body and a first finger, wherein the first finger is located in a different plane from the first arm body, the spring clip is slidably secured to the bracket body and movable between a closed position and an open position;
wherein in the closed position, the first finger is positioned at least partially within the arch wire slot to occlude the arch wire slot; and
wherein in the open position, the first arm is deformed to move the first finger out of the arch wire slot.

US Pat. No. 10,653,504

ELECTROMECHANICAL SYSTEMS, METHODS, ORTHODONTIC BRACKETS, AND TOOLS FOR ADJUSTING ORTHODONTIC PRESCRIPTIONS OF ORTHODONTIC BRACKETS WITH ADJUSTABLE ARCHWIRE PASSAGES

1. A method of adjusting an orthodontic bracket that includes an archwire slot while the orthodontic bracket is operatively attached to a patient's tooth, the method comprising:operatively engaging the orthodontic bracket with an engagement structure of an electronic orthodontic adjustment tool;
electronically determining a present orientation of the archwire slot relative to a reference orientation at a given point in time;
displaying a displayed orientation of the archwire slot with the electronic orthodontic adjustment tool, wherein the displayed orientation is based, at least in part, on the present orientation; and
adjusting the orientation of the archwire slot relative to the reference orientation based, at least in part, on the displaying.

US Pat. No. 10,653,503

DIGITAL DENTAL MODELING

Align Technology, Inc., ...

1. A system, comprising:a memory; and
a processor configured to execute instructions stored on the memory to:
receive:
a two-dimensional image corresponding to at least a portion of an upper jaw and a lower jaw of a patient; and
a three-dimensional digital dental model including the upper jaw and the lower jaw of the patient;
generate a treatment plan using the three-dimensional digital dental model;
correlate a number of first points marked on the two-dimensional image with a number of second points on the three-dimensional digital dental model of the upper jaw and the lower jaw of the patient;
set an initial position of the lower jaw of the three-dimensional digital dental model with respect to the upper jaw of the three-dimensional digital dental model based on the number of first points correlated with the number of second points and according to a class of occlusion associated with the patient's upper jaw and lower jaw of the three-dimensional digital dental model;
simulate anatomical movement by applying simulated forces to the lower jaw of the three-dimensional digital dental model, the simulated forces including an axial force, a number of photo attraction forces, and a number of reaction forces from interaction of the upper jaw and the lower jaw of the three-dimensional digital dental model;
report a bite set where the axial force, the number of photo attraction forces, and the number of reaction forces reach an equilibrium such that the lower jaw of the three-dimensional digital dental model ceases moving; and
cause a physical dental appliance to be created for a particular stage of the treatment plan based on the initial position of the lower jaw of the three-dimensional digital dental model with respect to the upper jaw of the three-dimensional digital dental model.

US Pat. No. 10,653,502

METHOD AND SYSTEM FOR PROVIDING DYNAMIC ORTHODONTIC ASSESSMENT AND TREATMENT PROFILES

Align Technology, Inc., ...

1. A computer-implemented method for designing orthodontic appliances to treat a patient's teeth, the method comprising:receiving digital data representing a scan of an initial arrangement of the patient's teeth;
customizing a treatment plan using a treatment planning learning algorithm, the treatment plan comprising one or more paths for moving the patient's teeth from the initial arrangement towards a final arrangement, wherein the treatment planning learning algorithm is trained on a database of previous treatment outcome data, the previous treatment outcome data including achieved and goal tooth movement data, and wherein the one or more paths are determined based on deviations between goal tooth movements and achieved tooth movements obtained from the database of the previous treatment outcome data;
determining, using the treatment planning learning algorithm, tooth surface geometries of one or more of the patient's teeth at a plurality of phases of the treatment plan; and
determining, using the treatment planning learning algorithm, appliance surface geometries of a plurality of polymeric orthodontic appliances for the plurality of phases of the treatment plan, the appliance surface geometries being associated with the tooth surface geometries for each of the plurality of phases of the determined treatment plan.

US Pat. No. 10,653,501

DENTAL ARTICLES AND METHODS OF USING SAME

3M INNOVATIVE PROPERTIES ...

1. A sealed package comprising an opening and an interior, and a seal overlying the opening, wherein the interior of the sealed package contains a dental article comprising: a shell in a shape of a crown, a bridge, a veneer, a tooth facsimile, or restoration, or an implant healing cap, the shell defining a volume and comprising a circumferential base and an incisal/occlusal region distal from the circumferential base, wherein the circumferential base of the shell defines an opening adapted to receive a dental structure; a hardenable dental composition located within the volume of the shell, wherein the hardenable dental composition exhibits a yield stress from 50 Pa to 4,000 Pa at 37° C., and wherein the hardenable dental composition comprises a photopolymerizable polymeric resin; and an isolation film, and an inset located within the shell of the dental article, wherein the inset comprises a material chosen from ceramics, glass ceramics, and composites of resins and ceramics.

US Pat. No. 10,653,500

SYSTEM AND METHOD FOR PREVENTING REUSE OF MEDICAL DEVICE

Gyrus ACMI, Inc., Southb...

1. A medical system comprising:a medical device configured to generate a first code or coded message; and
a controller, where the controller is configured to be in electronic communication with the medical device, where the controller comprises a processor and a memory, where the controller is configured to generate a second code or coded message based upon information received from the medical device, where the controller is configured to transmit the second code or coded message to the medical device,
where the medical device is configured to block the medical device from being used when the first code or coded message and the second code or coded message are not the same or identical.

US Pat. No. 10,653,499

INTEGRATED SURGICAL IMPLANT DELIVERY SYSTEM AND METHOD

Spinal Generations, LLC, ...

1. A system comprising a processing circuit and a communications interface, wherein the processing circuit comprises:an inventory module configured to track an inventory of medical devices;
a usage module configured to generate usage data in response to use of one or more of the medical devices;
an ordering module configured to generate a purchase order based on the usage data, the purchase order involving two or more parties; and
a billing module configured to:
determine whether each party involved in the purchase order is eligible to use an incentive system;
determine incentive options available to each eligible party;
provide the associated incentive options to each eligible party;
receive at least one incentive option selection; and
generate transaction details for the purchase order based on the at least one selection.

US Pat. No. 10,653,498

FIBER OPTIC AND SLIP RING ROTARY JOINT FOR SUSPENSION ARM

Stryker Corporation, Kal...

1. A medical suspension arm assembly comprising:a plurality of suspension arms, each adjacent pair of the suspension arms being connected to each other by a joint, with at least one of the joints comprising an infinite rotation joint;
the infinite rotation joint allowing the suspension arms at the infinite rotation joint to have unlimited rotation relative to one another, the infinite rotation joint comprising an electrical contact assembly and an infinite rotation fiber optic joint mounted within the electrical contact assembly, wherein the electrical contact assembly comprises a first portion that comprises a plurality of first electrical contacts and a second portion that comprises a plurality of second electrical contacts that contact the plurality of first electrical contacts, wherein the first portion is rotatably mounted to the second portion such that the plurality of first electrical contacts can rotate relative to the plurality of second electrical contacts, wherein the infinite rotation fiber optic joint comprises a rotor portion that is directly rotatably connected to a stator portion of the infinite rotation fiber optic joint, wherein the rotor portion is mounted to the first portion of the electrical contact assembly and the stator portion is mounted to the second portion of the electrical contact assembly, wherein a first end of the infinite rotation fiber optic joint is infinitely rotatable relative to a second end of the infinite rotation fiber optic joint about an axis that extends centrally through both the first end and the second end;
cabling including fiber optic cabling and at least one electrical power supply wire extending through each of the suspension arms and each joint, wherein a first fiber optic cable is connected centrally to the first end of the infinite rotation fiber optic joint and a second fiber optic cable is connected centrally to the second end of the infinite rotation fiber optic joint, and wherein the first fiber optic cable and the second fiber optic cable directly interface each other through the infinite rotation fiber optic joint; and
a wired medical unit connected to an end of the plurality of suspension arms;
wherein data and electrical power can be transferred along each one of the suspension arms through the cabling and across each joint, and wherein at least a portion of the data can be transferred through the infinite rotation fiber optic joint.

US Pat. No. 10,653,497

SURGICAL TOOL SYSTEMS AND METHODS

Globus Medical, Inc., Au...

1. A surgical robot system comprising:a dynamic reference base adapted to attach to a patient fixture instrument, wherein the dynamic reference base has reference retroreflective markers, which are configured to be tracked by a camera system, indicating a position of the patient fixture instrument in a camera coordinate system associated with the camera system;
a temporary registration fixture device adapted to be temporarily attached to the patient and having:
temporary retroreflective markers trackable by the camera system, indicating a location of a target anatomical structure in the camera coordinate system and
radiopaque markers indicating a location of the target anatomical structure in an image coordinate system defined by an imaging system, the temporary retroreflective markers being in a fixed position relative to the radiopaque markers;
wherein the surgical robot system has a processor configured to perform an initial registration of the target anatomical structure from the imaging coordinate system to the camera coordinate system by associating a spatial location of the radiopaque markers of the temporary registration fixture device in the image coordinate system to a spatial location of the retroreflective markers of the temporary registration fixture device in the camera coordinate system based on the fixed position relationship of the temporary retroreflective markers relative to the radiopaque markers;
wherein the processor of the surgical robot system is configured to transfer the initial registration of the target anatomical structure relative to the temporary registration fixture device to a subsequent registration of the target anatomical structure relative to the dynamic reference base based on a relative position relationship between the temporary retroreflective markers and the reference retroreflective markers; and
wherein the dynamic reference base is configured to track the target anatomical structure in the camera coordinate system after the subsequent registration occurs.

US Pat. No. 10,653,496

APPARATUS AND METHODS FOR IMPLANTING OBJECTS, SUCH AS A BRONCHOSCOPICALLY IMPLANTING MARKERS IN THE LUNG OF PATIENTS

VARIAN MEDICAL SYSTEMS, I...

1. A method of deploying a marker into a lumen within a body, comprising:advancing a distal end of a catheter to a desired position in the lumen within the body, wherein the distal end of the catheter is pre-loaded with and releasably retains the marker such that a portion of the marker extends beyond the distal end of the catheter before and during the advancement of the catheter and until deployment, the marker providing a rounded leading edge as the distal end of the catheter is advanced to the desired position in the lumen;
engaging an actuator to move a push wire contained in the catheter toward the distal end of the catheter to engage the marker, the push wire including indicator marks to delineate a predetermined distance to displace the push wire in order to deploy the marker; and
deploying the marker by moving the push wire toward the distal end of the catheter or by fixing the push wire in place and retracting the catheter toward a proximal end of the push wire.

US Pat. No. 10,653,495

METHODS AND SYSTEMS FOR DISPLAY OF PATIENT DATA IN COMPUTER-ASSISTED SURGERY

Mobius Imaging LLC, Shir...

1. A method for performing image-guided surgery using multiple reference marker devices fixed to a patient, the method comprising:obtaining patient images using an imaging device;
registering at least a first portion of the patient images in a first patient coordinate system associated with first reference marker device fixed to a bony structure of the patient at a first location:
registering at least a second portion of the patient images to a second patient coordinate system associated with a second reference marker device fixed to a bony structure of the patient at a second location that is different than the first location:
selecting between display of patient images registered to the first patient coordinate system and display of patient images registered to the second patient coordinate system in an image guided surgery system based on a proximity to the first and second locations;
detecting a relative movement between the first and second reference marker devices; and
notifying a user when the detected relative movement is greater than a threshold value.

US Pat. No. 10,653,494

HANDLE DEVICE FOR A SURGICAL LIGHT WITH VOICE CONTROL, AND SURGICAL LIGHT

1. A handle device which is prepared for attachment to a receiving body of a surgical light, the handle device comprising a housing including a disk-shaped hollow portion with a front wall and a rear wall being distanced to the front wall via a side wall, a handle receiving portion being tightly connected to the front wall and forming a receiving pivot that extends with its longitudinal axis perpendicular to and away from the front wall, a handle element including a sleeve portion that forms a handle surface in an exterior region and is detachably arranged on the receiving pivot in such a way that a voice control module comprising the housing is detachably connected to the handle element, wherein inside the disk-shaped hollow portion of the housing an electronic housing is placed and inside this electronic housing at least one acoustic sensor and a loudspeaker as an acoustic output unit are enclosed.

US Pat. No. 10,653,493

SURGICAL GLOVE SYSTEMS AND METHOD OF USING THE SAME

1. A surgical system, comprising:a surgical glove configured to be removably attached to a human hand, said surgical glove comprising:
a first surgical instrument attached to the surgical glove, wherein the first surgical instrument is nonremoveably, integrally attached to the surgical glove during formation of the surgical glove, wherein the first surgical instrument is coupled to a finger of the surgical glove;
a first switch attached to the surgical glove for controlling the first surgical support system; and
a first actuating element attached to a thumb of the surgical glove, wherein the first actuating element is a discrete element,
wherein the surgical glove is formed of a latex material or a non-latex material;
wherein the first switch is actuated when the first actuating element is placed in close proximity to the first switch, and
wherein a thumb of said surgical glove is free of surgical support systems.

US Pat. No. 10,653,492

MEDICAL INSTRUMENT AND SURGICAL SYSTEM

SONY CORPORATION, Tokyo ...

1. A medical instrument comprising:a contact portion configured to contact body tissue;
a drive unit configured to generate drive force for causing the contact portion to contact the body tissue;
a limiter mechanism configured to impose restriction on transmission of the drive force to the contact portion, in accordance with contact force of the contact portion with respect to the body tissue; and
a transmission unit configured to transmit the drive force generated by the drive unit to the contact portion,
wherein the drive unit includes a motor having a shaft, and a rotation member, comprising a pulley, configured to be driven by the shaft of the motor to drive the transmission unit,
the limiter mechanism is formed by the pulley slipping with respect to rotation of the shaft of the motor if contact force of the contact portion with respect to the body tissue becomes larger than a predetermined threshold, and
the slipping of the rotation member is caused by interlocking tolerance and material sliding properties of the pulley and of the shaft.

US Pat. No. 10,653,491

DEXTEROUS SURGICAL MANIPULATOR AND METHOD OF USE

Vanderbilt University, N...

1. A surgical manipulator, comprising:an internal working end having an internal joint; and
an external control interface linked to the internal working end for controlling the internal working end, the external control interface including:
a first lever and a second lever that together define a grip volume for a surgeon's hand when gripping and operating the first lever and the second lever, wherein at least one of the first lever and the second lever is pivotable about a first pivot axis (J), and
an external wrist joint linked to the internal joint for controlling the internal joint;
wherein the external wrist joint is positioned at least substantially within the grip volume, wherein the external wrist joint includes a second pivot axis (H) and a third pivot axis (G) that are offset from one another, the second pivot axis (H) being disposed between the first pivot axis (J) and the third pivot axis (G);
wherein the first lever, the second lever, and the first pivot axis (J) together are rotatable about the third pivot axis (G), and
a drive cable coupled between the internal working end and the control interface for mechanically linking the internal working end and the control interface,
wherein the external wrist joint includes a pulley about which the drive cable is disposed, the pulley defining the third pivot axis.